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Neurology is one of the oldest yet most enigmatic 
fields of medicine.  The reasons for this are many and 
this issue of the UWOMJ highlights just a few common 
explanations.   
The first is that the 
function of the brain is nearly 
impossible to separate from the 
impacts of its functions.  That is, 
neurological function produces 
thoughts and behaviours that 
serve to build communication, 
relationships, and culture.  In this 
way, neurology cannot be viewed 
without consideration of psychol-
ogy, psychiatry, even anthropol-
ogy.  While neurology is not 
unique in that its function and subsequent dysfunc-
tion have implications outside of medicine, it is the 
extent of this enmeshing that makes neurology 
particularly fascinating.  Naylor, Kudlow and Shu 
explore this theme in their examination of physical 
activity on cognitive functioning, and Wang, Suppiah, 
Jiang, Bahreini and Rhee question the role of sleep in 
memory consolidation. 
A second contributor to the complexity of 
neurology is the disconnect between structure and 
function.  Consider the heart: its function can be 
inferred by a careful examination of the valves, the 
vessels, and the layers of the walls.  Analogies have 
been drawn to plumbing and engineering to help 
explain the function of the heart.  In contrast, the 
brain affords no such luxury.  The structure of the 
brain offers few clues as to its function.  Instead, 
scientists and clinicians have relied on dysfunction in 
order to explain function.  It is through understanding 
disease that we have come to appreciate the normal 
function of the brain. 
As an historical example, the function of the 
recurrent laryngeal nerve was discovered when 
Galen’s scalpel slipped during an experiment on a pig.1  
The animal survived the operation, but no longer 
squealed like his cohort.  History could have taken a 
few roads from here;  Galen could have abandoned 
medicine, chastising himself for suboptimal surgical 
technique.  Instead he asked why the pig no longer 
squealed.  In this case, it was not a meticulously 
crafted experiment that led to discovery, but keen 
observation and an inquisitive nature. 
As Galen found, nature can present data 
without a structured laboratory environment.  This is 
not to say that neurological discover-
ies are accidents; it requires someone 
to notice the phenomenon and probe 
deeper.  The next step is to seek out 
similar cases, which makes the 
scientific literature so important.  In 
the grading of evidence, case reports 
are often viewed as inferior to 
randomized controlled trials.  But 
sometimes, as Galen found, one case 
can spark discovery.  For this reason, 
the UWOMJ prides itself on featuring 
case reports.  For instance, Hamidi 
describes a case of aggressive behaviour that was 
ultimately attributed to a brain tumour. 
The UWOMJ is grateful to the numerous 
individuals who contributed to this issue, including 
our editors, feature writers, advisory board, faculty 
reviewers, and advertisers.  With your ongoing 
support, we will continue to produce issues that will 
hopefully inspire, inform, and reignite your passion 
for medicine. 
 
 
Laura Hinz 
Senior Associate Editor 
 
 
References 
 
1. Gross, CG.  Galen and the Squealing Pig.  The  
Neuroscientist. 1998;  4(3): 216-221. 
Clinical procedures 
Introduction 
 
Cerebrovascular diseases are the third leading cause of 
mortality in Canada and the United States.1,2 Recent ad-
vances in the field of endovascular surgical (interventional) 
neuroradiology have enabled the treatment of these 
conditions using minimally invasive catheter-based technol-
ogy assisted by radiologic imaging. Boasting a reduction in 
recovery time and associated pain, these procedures are 
increasingly being utilized as an alternative to traditional 
surgical intervention.   
When applied in clinical practice, neuroendovascular 
interventional therapies are primarily used in one of two 
possible forms: 1) revascularization leading to reopening of 
blood vessels as used to treat acute ischemic stroke, arterial 
stenosis, and dural venous thrombosis; and 2) embolization 
leading to the occlusion of blood vessels as used in the 
treatment of aneurysms, arteriovenous malformations, and 
vascular tumors.  Utilizing this distinction, an exploration of 
the most common neurological conditions treated by 
interventional neuroradiologists – carotid artery stenosis 
and intracranial aneurysms – will be undertaken.   
 
Origins of interventional neuroradiology 
 
Historically, the roots of interventional neuroradiology can 
be traced back to the late 1920s, when Egas Moniz used 
iodides to visualize the cerebral vasculature on radio-
graphs.3 Several years later, the first attempt at catheteriza-
tion was successfully completed by Werner Forssmann 
when he placed a urinary catheter into his own antecubital 
vein and advanced it into his heart.4 In 1960, Luessenhop 
and Velasquez demonstrated that intracranial vessels could 
be catheterized,5 and by 1974, these advances had opened 
the door for Serbinenko to use flow-directed balloon tipped 
catheters for the treatment of intracranial aneurysms – the 
first time an endovascular approach was utilized for the 
treatment of a cerebrovascular disorder.6 In Canada, the 
pioneering work in this field was conducted at University 
Hospital in London, Ontario where Drs. Gerard Debrun, 
Fernando Viñuela, and Allan Fox established a neuroen-
dovascular centre to test and clinically apply Serbinenko’s 
methods.7 
Today, the basic principle of all neuroendovascular 
procedures involves percutaneous entry, usually through 
the femoral artery, although the brachial and radial arteries 
are also possibilities. In 1953, a Swedish radiologist, Sven-
Ivar Seldinger, introduced the procedure that is now 
commonly employed to obtain vascular entry by all vascular 
interventional disciplines.8 Figure 1 illustrates a modern 
approach to the Seldinger technique whereby the vessel of  
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Figure 1. Illustration of a modified Seldinger technique of   
arterial access through trocar cannulation, guidewire and sheath 
insertion, and cathether introduction. 
Interventional neuroradiology and the treatment of carotid artery stenosis 
and intracranial aneurysms 
 
Sandeep Dhaliwal (Meds 2013) and Edward S. Weiss (Meds 2012) 
Faculty reviewer: Dr. Andrew Leung, Department of Radiology, UWO 
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Interventional neuroradiology  
interest is commonly punctured by a trocar (hollow needle), 
and a guidewire is inserted through the needle. The 
guidewire is used to introduce a catheter (or sheath) which 
can be used to deliver an array of items to the target lesion. 
As such, guide catheters can be directed into the supra-
aortic vessel of interest to allow for the highly selective 
delivery of coils, embolic materials, and even drugs into 
regions of interest.9 Seldinger showed that his technique 
could be used to access all arteries in the body via the 
femoral route,10 and the current practice of using ultrasound 
to aid in vessel localization has raised its safety profile. 
 
Revascularization: carotid artery stenting 
 
The application of endovascular techniques is routinely 
used for the treatment of atherosclerotic disease involving 
the extracranial carotid, vertebral, subclavian and brachio-
cephalic arteries.  Initially treated using balloon angioplasty, 
interventional techniques have now progressed to the use of 
stent-supported angioplasty.  As such, this approach is 
currently offered as a therapeutic alternative to traditional 
methods of open surgery for patients who have failed 
maximal medical therapy, or those who present as poor 
surgical candidates.  Although there are numerous cere-
brovascular conditions for which revascularization is 
possible, its use in treating carotid artery stenosis remains 
by far the most frequent occurrence.11  
Carotid artery stenting (CAS) is typically performed 
under conscious sedation using local anaesthetic to enable 
neurologic monitoring of the patient during the procedure.12 
Following puncture of the femoral artery, selective cathe-
terization of the common carotid artery is achieved. Prior to 
proceeding, preliminary diagnostic angiography of the 
carotid bifurcation is done in a minimum of two planes to 
provide the operator with information about the anatomy of 
the patient. Anatomical considerations form the basis for 
choosing between various sizes and shapes of catheters. For 
example, in older patients, vessel elongation, tortuosity and 
dilation can necessitate the use of larger-diameter and 
hence stiffer catheters in conjunction with stiffer 
guidewires.13 Patients are intravenously infused with 
heparin, and once the operator has determined the appro-
priate interventional strategy, the guide wire is used to 
cross the stenosed segment. The stent is then deployed and 
correctly positioned under fluoroscopic control. 
Named after an English dentist who invented the 
device in the late 19th century, stents are metallic structures 
designed to maintain vessel patency. Self-expanding and 
balloon-expandable stents are available for use, and these 
devices are either composed of a thermal expansion alloy 
(nitinol) or stainless steel. Although numerous designs exist, 
stent selection does not appear to influence patient out-
come.12 Nonetheless, there are several drawbacks regarding 
the use of stents in treating cerebrovascular disease. Firstly, 
stent placement can initiate a robust cellular response, 
resulting in intimal hyperplasia that can cause restenosis of 
the affected area.  The overall restenosis rate (>50% 
decrease in vessel diameter) one year following CAS has 
been reported to be as high as 20.8% in some trials.14 
Additionally, stents are highly thrombogenic and patients 
are recommended to undergo several days of preoperative 
treatment with aspirin and clopidogrel.  Not surprisingly, 
experimental evidence suggests oral aspirin (325 mg/day) 
and clopidogrel (75 mg/day) display a synergistic effect on 
platelet aggregation inhibition, antithrombotic activity, as 
well as preventing restenosis.15,16 Finally, the risk of emboli-
zation caused by procedural manipulation poses a signifi-
cant risk to the patient. MRI studies suggest that upwards of 
15 percent of patients develop new ischemic lesions in the 
brain following interventional stenting of CAS, although half 
are asymptomatic.17 To reduce the microembolic burden 
associated with stenting, embolic protection devices (EPDs) 
are increasingly being used. Currently, two types of cerebral 
protection strategies can be employed: 1) distal protection 
in the form of an occlusion balloon or filter; or 2) proximal 
protection in the form of flow interruption or reversal 
devices.18 
 
Embolization: intracranial aneurysms 
 
An aneurysm is a dilation of a vascular structure and is 
particularly troublesome when it occurs in the cerebral 
circulation, as rupture can often cause catastrophic loss of 
neurologic function and death. The larger arteries at the 
base of the brain are predominantly affected, likely due to 
their unique morphology – thinner walls, lack of external 
elastic lamina, and lack of surrounding supporting tissue.19 
Traditionally, surgical obliteration of aneurysms has been 
the gold standard treatment, while endovascular interven-
tion was typically reserved for patients who are medically 
unsuitable for surgery or for those who refuse open surgery.  
For example, the location of some aneurysms, such as the 
intracavernous carotid artery and basilar apex, dictated a 
preference for endovascular intervention if possible.9 
Today, the majority of aneurysms are treated using coils. 
Embolization is typically carried out with the patient 
under general anaesthesia, and arterial access is achieved as 
outlined above for CAS.  Numerous strategies exist for the 
endovascular treatment of intracranial aneurysms depend-
ing on the nature of the lesion.  Commonly, aneurysmal 
occlusion is achieved by the use of the Guglielmi Detachable 
Coil system (GDCs).20 The aneurysmal sac is densely packed 
with coils until no further angiographic filling is seen. 
Approved for use in 1995, GDCs are electrolytically detach-
able platinum coils that offer the operator the advantage of 
being able to withdraw coils from the aneurysm and 
reposition them if the initial result is less than satisfactory.  
Alternatively, stents can be used as a scaffold to support 
detachable coils, particularly in the case of wide-necked 
aneurysms, as shown in Figure 2. In this scenario, a stent is 
deployed across the neck of the aneurysm, and the coils are 
delivered into the aneurysmal lumen via a microcatheter 
passed through the stent interstices. Occasionally the size 
and shape of the aneurysm precludes it from being em-
bolized by coils or surgically clipped, and therefore balloon 
occlusion of the parent artery is undertaken to stop all 
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blood flow to the aneurysm.21  
 
Conclusion 
 
The past decade has seen an explosion of minimally-
invasive procedures undertaken to treat various cere-
brovascular conditions. Currently, randomized trials 
evaluating the benefits of endovascular treatments are 
ongoing. As technological advances are made, the safety and 
efficacy of these procedures are expected to improve.  In 
this manner, techniques employed by interventional 
neuroradiologists offer a promising alternative to current 
therapeutic paradigms. 
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Figure 2. Stent serving as scaffold to support detachable coils in treatment of a 
wide-necked aneurysm. (Used with permission.) 
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Alzheimer’s disease: a review of diagnostic criteria 
 
Jai Prashanth Jayakar (Meds 2013) and Julie Huang (Meds 2012) 
Faculty reviewer: Dr. Christopher Brymer, Division of Geriatric Medicine, UWO 
Introduction 
 
Dementia is a syndrome in which affected individuals have 
impairment of memory and at least one other cognitive 
area, for example, orientation or comprehension.1 The 
diagnosis of dementia corresponds to a variety of etiological 
domains, from cerebrovascular disease to neurodegenera-
tive disease. However, Alzheimer’s Disease (AD), which is a 
neurodegenerative disease of uncertain origin and patho-
genesis, is the most common form of dementia in the 
elderly.2 
First described by Alois Alzheimer in 1906, AD is a 
currently incurable neurodegenerative disease that primar-
ily affects adults. Estimated to affect over 4 million Ameri-
cans, AD places a heavy burden on the healthcare system.1 It 
is very unusual for this disease to occur in individuals less 
than 60 years of age, and it is reported to have a slight 
predilection towards affecting women rather than men.3 
Early AD typically presents with an insidious onset of mild 
cognitive impairment, often in the form of short term 
amnesia, which may be confused with the effects of aging or 
stress.3 This is followed by progressive functional and 
cognitive impairment in multiple domains, with some 
studies reporting that the mean survival post AD diagnosis 
is around 3-8 years,4 depending on factors such as the 
severity of cognitive impairment and functional deteriora-
tion.5 In later stages, AD can manifest with non-cognitive 
neurological symptoms, such as myoclonus and seizures.  
The progress of AD clinically is often measured by mental 
status scales such as the Mini-Mental State Examination 
(MMSE) and the Clinical Dementia Rating Scale.3 However, 
these scales have their own limitations in terms of corre-
sponding with the rate of clinical decline.  
Currently, the only definitive way to secure a 
diagnosis of AD is through histopathological examination of 
brain tissue.3 However, this is neither feasible nor is it 
practised clinically except for confirmation of diagnosis at 
autopsy. Rather, the mainstays for establishing a working 
diagnosis of AD are clinical assessment criteria. In this 
paper, we explore these tools and discuss their shortcom-
ings in AD diagnosis. We also review some of tests that are 
useful in differentiating AD dementia from other major 
types of dementia.    
    
Clinical criteria for a diagnosis of Alzheimer’s Disease 
 
While a number of diagnostic criteria for AD based on 
clinical grounds have been proposed, two major sets of 
clinical criteria are used in North America to reach a 
working diagnosis of AD. Both these criteria take into 
account some well established features of AD, such as the 
history of insidious onset and progressive course of deterio-
ration, as well as evidence of cognitive impairment in 
multiple areas.3  Conducting a detailed cognitive and general 
neurological examination and evaluating the level of 
cognitive impairment and dementia using the MMSE 
provide the essential clinical information to which these 
criteria may be applied.   
 
NINCDS-ADRDA criteria 
 
In 1984, a task force established by the National Institute of 
Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) put forth a set of clinical criteria for 
diagnosis of probable AD.6 These are provided in Table 1. 
Additionally, the criteria put forth by the same group for 
possible AD, where the degree of suspicion is lower than 
with probable AD, are also provided in Table 1.  
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Probable Criteria 
 
• Dementia established by clinical  
examination and standardized brief mental 
status examination and confirmed by  
neuropsychological tests 
• Deficits in two or more areas of cognition 
• Progressive worsening of memory and 
other cognitive function 
• No disturbance of consciousness 
• Onset between 40 and 90 years 
• Absence of other systemic or neurologic  
disorder sufficient to account for the  
progressive cognitive defects 
Possible Criteria  
 
• Atypical onset, presentation, or progression 
of dementia without known etiology  
• Presence of another potentially causative 
systemic or neurologic disorder that is not 
thought to be the etiology of dementia in 
this case  
• Progressive deterioration in a single cogni-
tive domain in the absence of any other 
etiology  
Table 1. NINCDS-ADRDA criteria for diagnosis of AD.  
Adapted from Feldman et al.3  
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Alzheimer’s disease 
The validity and reliability of these criteria have been 
investigated by a number of studies, with some yielding 
optimistic conclusions. For example, one study showed that 
diagnoses of AD made based on these criteria are confirmed 
by autopsy in 87% of cases.7 A study by the National 
Institute of Mental Health Genetics Initiative found these 
criteria to have good reliability and validity, with a diagnos-
tic sensitivity of 80%.8 However, some criticisms of these 
criteria have also been made. For example, one study 
showed that the interrater reliability for AD diagnosis using 
these criteria was only low to moderate.9 Another study 
showed that these criteria were not effective in distinguish-
ing frontotemporal dementia from AD dementia in a group 
of 56 patients.10 This lack of specificity has been attributed 
to be a result of inadequate emphasis of the saliency of the 
amnesia component of AD.3 Furthermore, since the NINCDS-
ADRDA criteria are fairly old, they may not reflect recently 
discovered biomarkers and genetic findings that can help 
support an AD diagnosis.  
 
DSM-IV-TR criteria 
The other commonly used clinical criteria for AD diagnosis 
are derived from the current version of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) pub-
lished by the American Psychiatric Association.11 These 
criteria are provided in table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One argument in favour of the DSM-IV-TR criteria is that 
they do not necessitate neuropsychological testing in 
making a diagnosis. However, in a study of 200 patients that 
compared the NINCDS-ADRDA criteria and the then-current 
DSM criteria (DSM III-R) against the gold standard of 
histopathological examination, the NINCDS-ADRDA prob-
able and possible criteria together were found to be 61% 
specific, 96% sensitive, and 85% accurate in detecting AD 
while the DSM criteria were found to be 51% sensitive, 96% 
specific, and 66% accurate in detecting AD.12 Another study 
showed that the interrater reliability between the NINCDS-
ADRDA and the DSM-III criteria are comparable,13 and an 
evidence-based review written by the American Academy of 
Neurology (AAN) in 1994 concluded that both sets of 
criteria for AD diagnosis were sufficiently reliable and valid 
and that they should be used.14 More recent evidence 
indicates that documenting an objective progression of 
cognitive decline over a 12-18 month period is both highly 
specific and sensitive for AD,3 however, this is logistically 
hard to execute.  
 
Excluding other causes of dementia 
 
As mentioned earlier, dementia can be present in a wide 
variety of neurological disease entities. Excluding depres-
sion is an important part of diagnosing dementia. Depres-
sion is more common in old age than dementia, and is 
treatable. Chronic pain and medication side effects can also 
be confused with dementia, therefore, clinical assessments 
need to be thorough in order to delineate these other non-
AD causes of cognitive decline.   
Laboratory and imaging technologies can also be 
helpful in ruling out non-AD diagnoses of dementia. For 
example, according to guidelines issued by the AAN, brain 
imaging, preferably MRI, is indicated in those patients with 
suspected AD.14 This is important because imaging can 
reveal structural problems (e.g. hematomas), brain atrophy, 
and cerebrovascular disease, which can all present similarly 
to AD. Specific imaging features for AD diagnosis have not 
been firmly established, though some studies have reported 
reduced hippocampal volume to be correlated with AD.15,16 
However, there is also evidence that AD and aging exhibit 
substantially overlapping atrophy patterns in the hippocam-
pus and entorhinalcortex, so age-specific criteria are 
required.17 Special imaging techniques (e.g. fluorodeoxyglu-
cose-positron emission tomography) have been developed 
that can highlight areas of hypoperfusion in AD or that can 
reveal imaging features that distinguish AD from other 
diseases causing brain atrophy.18 However, these techniques 
need to be evaluated further for their ability to provide 
information that affects therapeutic decision making; 
distinguishing between clinical entities whose treatment is 
the same does not help. They are also not universally 
available, and they are not routinely used for AD at present.  
Laboratory tests are useful in ruling out other 
factors that can contribute to dementia. For example, B12 
deficiency, which affects homocysteine and methylmalonyl-
CoA metabolism, is associated with irreversible neurological 
damage.19 Hypothyroidism can also contribute to a demen-
tia-like presentation, therefore screening for B12 deficiency 
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1. The development of multiple cognitive 
deficits manifested by both: 
 
· Memory impairment 
· One or more of the following cognitive  
  disturbances: aphasia, apraxia, agnosia,   
  disturbance in executive functioning. 
 
2. The cognitive deficits cause significant 
impairment in social or occupational func-
tioning and represent a significant decline 
from a previous level of functioning. 
 
3. The course is characterized by gradual 
onset and continuing decline. 
 
4. The deficits are not due to another brain, 
systemic, or psychiatric condition. 
 
5. The deficits do not occur exclusively  
during the course of delirium. 
 
Table 1. DSM-IV-TR criteria for diagnosis of AD.  
Adapted from Feldman et al.3  
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and hypothyroidism is important. However, clinicians 
should not order multiple laboratory tests unnecessarily: 
some studies show that this is not a cost-effective process, 
owing to the relative rarity of a treatable metabolic cause of 
dementia.20 Given the right clinical picture (e.g. a patient 
with chronic alcoholism, in whom B12 deficiency is likely), 
laboratory tests are warranted. A number of studies have 
revealed that serum or CSF levels of a beta-amyloid peptide 
(called Aβ 42), which is suspected to play a role in AD 
pathogenesis, may be predictive for AD in patients with mild 
cognitive impairment, but these measurements have not 
been formally included in clinical practice guidelines yet.21 
Genetic testing does not have a routine role in AD diagnosis, 
but some evidence suggests that testing for presenilin-1 
mutations may be considered on a case-by-case basis in 
unusual presentations of disease, for example in young 
patients with a strong family history, when appropriate 
genetic counselling is provided.22  
 
Conclusion 
 
In this paper, we have reviewed some major clinical criteria 
that are used in making a provisional diagnosis of AD and 
reported on the literature evaluating the credibility of these 
criteria. While the NINCDS-ADRDA guidelines have been 
used for a long time and have been shown to have reason-
able validity and reliability, they are lacking in specificity, 
and need to be updated to incorporate the latest advances in 
diagnostic technology. Studies have found the DSM-III-R 
criteria to be comparable to the NINCDS-ADRDA diagnostic 
criteria, however, there is a clear dearth of research in 
evaluating the value of the DSM-IV-TR criteria for AD. In 
addition to these clinical criteria, other tests such as 
neurological imaging and serum B12 tests, can be valuable 
in excluding non-AD differential diagnoses of dementia. 
Given that the DSM-V is slated for publication in 2012, we 
hope that the AD criteria published therein will incorporate 
the merits of existing criteria with additional criteria that 
reflect our expansion of diagnostic knowledge and tools in 
this area.  
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Should physicians be taking cognitive-enhancing drugs?  
 
Hang Shi (Meds 2013) 
Faculty reviewer: Dr. Lois Champion, Departments of Critical Care and Anesthesia, UWO 
With the advent of the pharmacological age, a brave new 
world where the neurological enhancement of the human 
mind through chemical substances is no longer confined to 
the realm of science fiction. Variously described as cognitive 
enhancing drugs, smart drugs, or nootropics, there is an 
ever-growing list of drugs on the market that can improve 
mental function such as memory, attention, motivation, and 
concentration.1 While initially researched for the therapeu-
tic treatment of psychiatric disorders such as Alzheimer’s 
and Attention-Deficit Hyperactivity Disorder (ADHD), there 
is increasing evidence that various stimulants and anti-
depressants are being used off-label for the enhancement of 
mental performance in healthy individuals.2  
The controversial use of these drugs by university 
students and the military has been well documented in the 
literature.2 However, physicians have not been a focus in the 
discussion despite being a susceptible demographic group 
with predisposing risk factors. The high levels of stress, 
fatigue, and pressure especially prevalent among residents 
and certain shift work specialties, such as emergency 
medicine,3-5 may make the use of these cognitive-enhancers 
appealing. As a result, a candid discussion of the ethical 
implications is well warranted. This article examines the 
relevant ethical arguments that are important in determin-
ing whether physicians should be taking cognitive-
enhancing drugs.   
 
 The wisdom of repugnance: the “yuck” factor 
 
While the use of neuro-altering drugs is widely deemed 
morally acceptable as a medical intervention in neurological 
disorders, the use of these same drugs in healthy individuals 
often elicits guttural reactions.6,7 The use of amphetamines 
for narcolepsy is not met with nearly the same outcry as its 
use by ambitious university students to improve test scores. 
Once the line crosses from treatment of disease to enhance-
ment of normal function, a fundamental change in accept-
ability seems to occur. One explanation is that the process of 
cognitive improvement through a pill is unnatural or 
inauthentic.8 However, our use of other more common 
chemical remedies to enhance cognition is not anything new 
or fundamentally more “natural.” The widespread use of 
caffeinated beverages is a form of cognitive-enhancement,9 
but has not evoked public scrutiny or protest. Why should 
the ethical considerations change depending on whether the 
medium is in the form of a drink or pill?  
Some arguments that call into question whether 
there is anything intrinsically wrong with medicating to 
enhance cognitive function may border on begging the 
question, but nevertheless have their implications. If the 
very principle of medicating the healthy is unethical, then 
advocating for pharmacological enhancement within a 
profession where public perception and patient trust is so 
important may be imprudent.  
 
Maximizing utility and the creation of SuperDocs  
 
The use of cognitive enhancing drugs by physicians can 
potentially improve the well-being of both physicians and 
their patients. The well-documented high levels of fatigue, 
sleep-deprivation, and stressful environments that physi-
cians endure have been shown to lead to lowered vigilance 
and an increase in medical errors.10 In a double-blind 
placebo controlled study with sleep deprived emergency 
physicians, the stimulant modafinil (Provigil®) was shown 
to improve cognitive ability by improving sustained 
attention as well as increasing cognitive control and 
working memory.11 It is not a far stretch to consider how 
more attentive, alert, and cognitively functioning physicians 
can reduce medical errors, improve productivity, and have 
the fortitude to be more patient-centred in their approach. 
Not only would this benefit patients by improving their 
health outcomes, it would benefit the physician by lowering 
their levels of anxiety and stress, and may even benefit the 
health care system by improving physician efficiency. If a 
hypothetical ideal cognitive enhancer can augment desired 
and predictable changes in mood, personality, attention, and 
memory, society as a whole may be better off. From a 
utilitarian point of view, the potential benefits of cognitively 
enhanced physicians may be too great to ignore with ever-
progressing advances in pharmacological agents.  
 
Primum non nocere 
 
Therapeutic agents have inherent risks and the potential for 
harm; the maxim of “first, do no harm” remains a fundamen-
tal principle of medicine and serves as a reminder of how 
purported beneficial interventions often have unforeseen 
and undesirable consequences. While psychotropic drugs 
such as stimulants and anti-depressants are widely pre-
scribed medications with few side effects,13 even minimal 
risks need to be taken into account when used by healthy 
individuals. While patients with severe symptomatic 
neurological deficits may tolerate the risks involved, the 
threshold of risk tolerance is significantly lower for healthy 
individuals.14 In the study of the use of modafinil among 
sleep-deprived physicians, the treatment group found it 
more difficult to sleep when the opportunity arose.11 While 
sleep-deprived physicians could use the drug to maintain 
attention and cognitive function in the short term, the 
resulting trade-off may lead to a Faustian bargain. Even 
worse, the long term effects of these psychotropics are 
largely unknown.15 The pendulum would certainly take a 
devastating swing from benefit to harm if a generation of 
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medicated and neurologically enhanced physicians were 
later found to suffer from cognitive decline or memory loss 
in later years. Unfortunately, when faced with the proposi-
tion of obtaining immediate tangible benefits from these 
neurological enhancers, these hidden costs may not be 
taken into account when considering their use.16 Given the 
propensity of human nature to value short term results, as 
exemplified by the popular use of sildenafil (Viagra®) and 
cosmetic use of botulism toxin (Botox®), the potential for 
the overuse and abuse of these pharmacological remedies is 
a concern.  
 
“But everyone else is doing it” 
 
One of the most commonly cited issues with the use of 
cognitive enhancing drugs by university students is its 
perception as a form of cheating, and one could argue that 
ambitious residents or physicians who take these cognitive 
enhancers to “get ahead” violate the sanctity of fair competi-
tion on an even playing field.1 Although the field was never 
strictly even to begin with due to socioeconomic, genetic, 
and environmental determinants, improving productivity 
through artificial pills may undermine the value of effort 
and hard work.16 The issue especially becomes problematic 
if there is an unequal distribution of use amongst different 
physicians or different specialties. Should use only be 
recommended for specialties with the highest levels of 
fatigue, sleep deprivation, and stress? Should only those 
physicians deemed most in need, namely those with the 
worst attention and cognitive ability, be prescribed these 
enhancers? 
 If there are no regulations in place, unintended and 
indirect coercive forces may come into play where physi-
cians who otherwise would not have taken these enhancers 
now feel compelled to do so. If doctors who use the cogni-
tive enhancing drugs achieve improved performance and 
are perceived as superior by patients or colleagues, this puts 
increased pressure on and makes it more difficult for those 
who would otherwise opt out.1 Furthermore, with the 
emphasis today on outcomes-based medicine and the 
importance of hospital ratings on budgets, there may also be 
external pressure from the employer or administration. In 
the event that these drugs could approach a pharmacologi-
cal ideal with maximum benefit and negligible harm, could 
these cognitive enhancers become as compulsory as 
scrubbing in to protect the safety of the patients?   
 
Conclusion 
 
While a number of ethical issues are left largely unexplored, 
such as personal identity, distributive justice, or intangible 
values, a cursory discussion concerning beneficence, 
nonmaleficence, as well as autonomy has been attempted. 
Currently, with our poor understanding of the long-term 
risks of these cognitive-enhancing drugs, the potential for 
serious harm seems to outweigh the marginal cognitive 
benefits observed in healthy individuals. The use of these 
drugs is likely a reflection of our society and medicine as a 
practice, where the ‘quick fix’ is often the most attractive 
strategy.1 Alternative solutions certainly exist, such as 
optimizing shift schedules and improving work-life balance. 
These strategies present less risk and address the root of 
the problem: over-work, sleep-deprivation, and fatigue.19 
However, as drug advances are made with improved 
performance records and as better understanding of the 
long-term effects become available, the reality is that a 
growing number of people will practice neurocognitive 
enhancement in the coming years. The sale of various 
nutritional supplements that are purported to have cogni-
tive-enhancing function have reached a billion dollars 
annually in the United States alone, and market demand is 
projected to rise.14 Given the easy accessibility of drugs to 
physicians and compounded with their propensity to self 
prescribe,17,20 the discussion concerning the guidelines and 
regulations for the use of cognitive-enhancing drugs needs 
to begin now.   
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Introduction 
 
Healthy behaviours learned early in life are more likely to 
persist into adulthood. As such, there is a strong prima facie 
case for health promotion interventions that target young 
Canadians. That case is strengthened by the fact that risk 
factors emerging early in life will take a cumulative toll and 
could have debilitating consequences on future health.  
One such risk factor is physical inactivity. Attention 
in the past has tended to focus on the relationship of 
inactivity among adults to increasing prevalence of risk 
factors for chronic cardiovascular disease, viz. higher rates 
of obesity, dyslipidemia, diabetes, and hypertension.  Today, 
however, there is growing interest in the long-term effects 
of inactivity that commences in childhood. As summarized 
below, physical inactivity is not only linked to the growing 
epidemic of childhood obesity; contemporary evidence also 
links higher activity levels to enhanced learning and raises 
the possibility that exercise may be very important in 
healthy cognitive development.    
 
The childhood obesity epidemic 
 
Obesity has become increasingly prevalent among Canadian 
children and youth. Temporal trends can be appreciated by 
defining a reference population and thresholds, e.g. over-
weight as body mass index (BMI) above the 85th percentile, 
and obesity as BMI above the 95th percentile for a reference 
population. Using 1981 weight distributions as a baseline or 
reference group, one study of Canadian children aged 7–13 
years found that the prevalence of overweight among boys 
increased from 15% in 1981 to 35.4% in 1996 and among 
girls from 15% to 29.2%.1 The prevalence of obesity in 
children roughly tripled over that period, from 5% to 16.6% 
for boys and 14.6% for girls.  
Particularly in North America, physical inactivity is 
one of the major causes of obesity.  Increased caloric intake 
is also important, but the two may well interact.  For 
example, Crespo et al. reported that US children who 
watched 5 or more hours of television per day consumed on 
average 175 kcal per day  more than children watching not 
more than 1 hour per day. 2  Both organized and unorgan-
ized sport and physical activities have been shown to reduce 
the risk of being overweight by 10–24%, and of being obese 
by 23–43%, after controlling for sex, family structure, and 
socioeconomic status.3 In addition to effects on body fat, 
cross-sectional studies have shown an association between 
higher activity levels and increased bone mineral mass and 
lower levels of tobacco and alcohol use in young people.4 
Not surprisingly given the progressive increase in 
childhood obesity, school-based physical activity rates are 
alarmingly low amongst young people. The American 
Academy of Paediatrics (AAP) recommends comprehensive, 
preferably daily, physical education (PE) for children in 
grades Kindergarten through 12.4 Despite this recommenda-
tion, only 3.8% of all elementary schools, 7.9% of all middle 
schools, and 2.1% of all high schools in the United States 
provide daily physical education for all students.5 Data from 
Ontario high schools are also discouraging. Between 1999 
and 2005, there was a significant linear decrease in the 
percentage of students who were enrolled in PE: from 
70.3% in 1999 to 60.3% in 2005.6 
Adolescence may be a time of particular concern, as 
academic pressures increase and many schools favour 
classroom time over physical education.  Indeed, one study 
examining high school students in Ontario found a steady 
decline in physical activity between 14 and 18 years of age.7 
However, even pre-adolescents are not active enough. In 
2002, approximately 82% of Canadian children aged 9 to 12 
were not active enough to meet international guidelines for 
normal growth and development.8  
 
Gym in schools and academic performance 
 
School-based physical activity interventions are seen as 
desirable since students are a “captive audience” during 
weekdays.  There has been a presumption in some quarters, 
however, that time spent outside of the classroom on 
physical activity may decrease the academic performance of 
pupils. Fortunately, several studies have shown that time 
spent on physical education has no negative effects on 
overall academic attainment.   
In one study of 117 Australian primary schools, time 
spent in physical education was not negatively related to 
average school attainment in either literacy or numeracy.9 
Similarly, a study from British Columbia found that a school-
based intervention offering an additional 15 minutes of 
physical activity a day did not reduce levels of academic 
performance among students.9  Instead, the evidence 
suggests that physical activity may enhance the academic 
performance and cognitive functioning of young students.  
One meta-analysis sought to aggregate the results of 44 
studies pertaining to physical activity and cognition in 
children, and found a significant positive relationship.8 
Middle school students (grades 6-8) and elementary age 
students showed the largest cognitive benefit from physical 
activity. The type of activity was not a significant moderator 
variable, suggesting that any type of physical activity had 
beneficial effects.   
Notwithstanding the results of the meta-analysis by 
Sibley et al.,10 some newer evidence supports the notion that 
different forms of physical activity may actually mediate 
specific cognitive effects. One study examined the perform-
ance of 115 healthy adolescents aged 13-16 years on a test 
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of attention and concentration. Students performed the test 
after receiving either coordinative exercise, normal exer-
cise, or a classroom lesson. Both the coordinative and 
normal exercise groups showed enhanced test performance, 
but coordinative exercise was the most effective. The 
authors hypothesized that coordinative exercise might lead 
to a ‘pre-activation’ of areas of the brain which also mediate 
attention and other cognitive functions.11  As well, Coe et al. 
suggest that intensity may also be a factor.12  They found 
that students who performed vigorous activity had signifi-
cantly higher grades than students who performed none, 
while moderate physical activity did not affect grades.   
Castelli et al. suggest that these effects accumulate 
through an overall fitness effect, rather than being related 
solely to recent exercise. 13 They examined 259 public 
school students in third and fifth grades and found that 
aerobic capacity was positively associated 
with achievement, whereas BMI was inversely related.  
Also relevant are the results of a systematic review 
of 23 randomized controlled trials addressing exercise and 
self-esteem.  The review found that exercise has positive 
short-term effects on self-esteem in children and young 
adults.14 It has been hypothesized that improved self-esteem 
may help to reduce or prevent psychological and behav-
ioural problems in children this age group, which may 
ultimately augment classroom performance. 
 
Mechanisms for the neuropsychological effects of 
exercise 
 
These positive effects of exercise on learning in childhood 
and adolescence are striking, and, encouragingly, appear to 
be generalized to adult disorders.  For example, increased 
physical activity may delay the onset of Alzheimer dis-
ease, Huntington's disease and Parkinson's disease.  There 
is also some evidence to suggest that exercise mitigates the 
pace of functional decline after neurodegeneration has 
begun.  Furthermore, while the mechanisms are not well 
understood, exercise also seems to have both positive 
effects on depression and anxiety, among other psychiatric 
disorders.15  
As sometimes happens, these empirical findings are 
still not well-explained by the available basic science.  One 
line of evidence suggests that neurogenesis – i.e. the 
production of new neurons – is important.  Exercise clearly 
stimulates neurogenesis in a portion of the hippocampus 
that affects learning and memory.15 Since these new 
neurons appear to have lower thresholds for activation, 
neurogenesis could well underpin some of the positive 
cognitive effects of exercise.  In particular, Pereira et al. 
showed that after 12 weeks of cardiovascular exercise 
training, there was an increase in blood flow to the hippo-
campal region in rodents and humans. 16 This increase was 
positively correlated with improved rates of learning a 
hippocampus-dependent task.  While a variety of growth 
factors appear to play a role in mediating these blood flow 
effects, no specific therapeutic role for those factors has 
been elucidated thus far.  
An alternative explanatory approach – less relevant 
to children and youth – is to focus on the risk factors for 
cognitive decline and delineate those that could be related 
to physical activity.   Among the risk factors for cognitive 
decline are hypertension, hyperglycemia, insulin insensitiv-
ity and dyslipidemia, a cluster of features encompassed by 
the ‘metabolic syndrome.’  Exercise reduces the impact of all 
these risk factors. Thus, whether through direct central 
neurological effects or through neuro-protective effects 
mediated in part by mitigating cardiovascular risk fac-
tors, exercise seems likely to shape neurological develop-
ment across the life course.15 
 
Future directions 
 
According to Canadian estimates for 2001, the economic 
burden associated with physical inactivity was $5.3 billion.17 
Thus, interventions targeting physical activity have the 
potential to show large ‘returns on investment’. As already 
argued, the logical place to start promoting physical activity 
is childhood, in part to combat the epidemic of obesity 
among children and youth.  Indeed, we know that children 
who are obese in their preschool years are more likely to be 
obese in adolescence and adulthood and to develop diabe-
tes, hypertension, hyperlipidemia, asthma, and sleep 
apnea.18  
Greater levels of physical activity among children 
and youth may also lead to enhanced cognitive functioning.  
However, much more can be done to elucidate mechanisms 
and clearly delineate exercise modalities.  Whereas hu-
man studies have emphasized frontal-brain-dependent 
tasks (i.e. executive function), animal studies have focused 
on hippocampus-dependent learning and plasticity. There 
also remains a need for clarification as to which types of 
exercise, and at what duration and intensity, will have the 
optimal impacts on cognitive outcomes.  Confounders 
abound in observational studies; physical activity levels 
may be associated with other mediating variables such as 
socioeconomic status. Thus, to fine-tune the various 
interventions, formal randomized trials are essential with 
standardized outcome measures.   
It seems defensible, however, to proceed sooner 
rather than later with policy shifts that will promote 
physical activity among children and youth.  From a policy 
standpoint, we applaud Ontario’s Healthy Schools program. 
It was announced in 2005 that every Ontario elementary 
student will take part in a minimum of 20 minutes of daily 
physical activity. This initiative aimed to complement 
existing physical education classes that occur twice or three 
times a week for 30 to 40 minutes for elementary stu-
dents.19 We would strongly encourage similar policies for 
middle and high school students.  
Last, we also encourage the development of a 
rigorous agenda of basic, translational and applied research 
that will clarify how best to promote physical activity across 
the life course.       
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History of medicine 
Reflux, revolution, and the role of forgotten research in medical paradigms 
 
Edward S. Weiss (Meds 2012) 
Faculty reviewer: Dr. Paul Potter, Department of History of Medicine, UWO 
Introduction 
 
The conventional view of science as a plodding, methodical 
process free of entrenched interests and proceeding solely 
on the basis of observable facts permeates popular thinking. 
Scientists are often seen as seekers of truth, garbed all in 
white, using their sheer brainpower to piece together the 
innumerable parts of whatever grand puzzles capture their 
respective imaginations. In truth, though, science often 
progresses not only by evolution, but by revolution as well. 
In his seminal work of scientific sociology, “The Structure of 
Scientific Revolutions,”1Thomas Kuhn put forward the 
notion of the paradigm shift as the major mechanism for 
scientific change, and although the term has been popular-
ized – almost to the point of losing its original meaning – it 
still retains immense relevance for the analysis of current 
events in the scientific and biomedical realms. 
Kuhn posited that research into a particular scien-
tific or medical problem takes place within the context of a 
research programme, an overarching framework that 
dictates the shape of the overall problem, as well as the 
nature of the specific results needed to solve it. It is perhaps 
best compared to a partially-solved jigsaw puzzle, in which 
the dimensions of the puzzle are clear, and the shapes of the 
missing pieces are discernible – one only has to find the 
missing pieces that fit into particular spots to complete the 
puzzle and construct a coherent image. However, some-
times one is left with puzzle pieces that don’t seem to fit 
anywhere, and empty spots for which suitably-shaped 
pieces cannot be found. In this case, one is forced to ques-
tion whether the attempt at the puzzle is, indeed, correct, or 
if perhaps the puzzle depicts something entirely different 
and needs to be rebuilt from scratch.  
Such is the case with science as well: data that pose 
challenges to the dominant framework accumulate, and 
important research questions go unanswered by the 
research programme currently underway. A new theory is 
put forward that accounts not only for the previously 
established results, but also for the conflicting data that 
troubled the dominant paradigm, and while the new 
approach may not answer every remaining question, it does 
provide a direction for further research to follow. However, 
as will be demonstrated shortly, there is often considerable 
opposition to the introduction of a new paradigm. Careers 
and fortunes are often staked upon a widely-held paradigm, 
and even though researchers may have the best of inten-
tions, the words of Max Planck too often hold true: "a new 
scientific truth does not triumph by convincing its oppo-
nents and making them see the light, but rather because its 
opponents eventually die, and a new generation grows up 
that is familiar with it."1 
 
The case of peptic ulcers 
 
The classic example of a paradigm shift in medical thinking 
relates to the etiology of peptic ulcers. Originally described 
by Marcello Donati in 1586,2 gastric ulcers in particular 
came to be attributed to the acid milieu of the stomach, 
encapsulated in the famous proclamation of the Croatian 
surgeon Karl Schwatz: “No acid, no ulcer.” Factors which 
increased the amount of acid, such as stress and spicy food, 
were naturally seen as contributing to the pathogenesis of 
the dread disease. However, blaming acid alone for the 
incidence of ulcers left several important facts unexplained. 
For one thing, until the advent of effective antacid medica-
tion, the prescribed treatment was often ineffective. More 
fundamentally, as early as 1875, it was proposed that 
bacteria had a role to play in the development of peptic 
ulcers, and in the late 1950s, it was recognized by some 
clinicians that ulcers could be successfully treated with 
antibiotics. The Greek physician John Lykoudis, for example, 
discovered that his chronic ulcer problem went into 
remission after he treated himself with antibiotics for a bout 
of gastroenteritis. He later took out a patent on his antibiotic 
ulcer preparation and attempted to publish an article in 
JAMA, only to be summarily rejected.3 Lykoudis was 
eventually fined 4,000 drachmas (about $900, accounting 
for inflation) by the Greek medical disciplinary committee 
for his unorthodox treatment,4 and the bacterial theory of 
peptic ulcers resumed its usual lowly place in the dominant 
paradigm until the work of Marshall and Warren in the 
1980s finally set into motion the wheels of scientific 
revolution and established that gastric infection with H. 
pylori was a major cause of peptic ulcers. 
What this paradigm shift serves to highlight is the 
role of forgotten research, the undercurrent of data sup-
porting alternate etiological factors that were never 
incorporated into the dominant paradigm. That this 
research is generally ignored – or censured, as in the case of 
Lykoudis – is, in retrospect, difficult to justify scientifically, 
but ultimately understandable. Before the attribution of 
peptic ulcers to acid and acid alone, research in this area 
was in what Kuhn called the pre-paradigm phase, in which 
there is no consensus on a research programme, but the 
research being conducted is nonetheless valid and scientific. 
When the consensus of an acid etiology was reached, 
research began operating in the second phase of Kuhn’s 
hierarchy: normal science, in which experiments and 
studies are conducted with the aim of filling in the missing 
pieces of a defined puzzle. Concurrent with the ascendancy 
of a particular paradigm is the frequent abandonment of 
earlier, pre-paradigm directions in research, not because of 
inherent invalidity, but because circumstances are such that 
further exploration is unfeasible: researchers may change to 
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a different field of study, there may not be sufficient 
supporting knowledge or technological gadgetry to investi-
gate a theory, or sources of funding may shift to approaches 
that support the alternate, ascendant theory. When a 
dominant paradigm is established and other theoretical 
approaches are no longer en vogue, it is easy to all but forget 
the historical context that gave rise to the current situation, 
especially when the next generation of researchers comes 
through the ranks having not even been informed of any 
alternative theories to the dominant one.   
Forgotten though they may be, alternate theories 
and dusty old data often survive in some form or another. In 
some cases, researchers outside the mainstream may 
continue to investigate older approaches, earning the scorn 
of their colleagues and collecting very little in the way of 
grant money and prestige. Alternatively, a researcher may, 
like John Lykoudis, discover quite accidentally through his 
or her own personal experience, that the current paradigm 
is lacking. Furthermore, an older theory may be resurrected 
when contemporary researchers independently turn up 
data that force them to dig through the literature for 
theories that might explain their findings. Thus, forgotten 
research has a vital role in maintaining one of the ultimate 
principles of scientific enquiry – that current knowledge is 
always subject to revision. 
 
Forgotten research in neurology 
 
Neurology is certainly a field that has its share of unsolved 
problems. The causative factors behind such diseases as 
epilepsy, ALS, and Parkinson’s are still mostly unknown, 
even if we have made progress towards understanding their 
pathophysiology. Of all the theories currently circulating 
that attempt to explain some aspect of neurological disease, 
there is perhaps none as recently controversial and widely-
publicized as the vascular theory of multiple sclerosis (MS), 
which contests the widely-held notion that MS is predomi-
nantly an auto-immune phenomenon. While this author is 
not in a position to comment on the ultimate validity of the 
theory, or the degree to which it explains the phenomena it 
claims to account for, an analysis of the issues surrounding 
the theory and the potential it has for sparking revolution-
ary science is worth contemplating. 
As was the case for peptic ulcer disease, there have 
seemingly always been multiple theories accounting for the 
pathogenesis of MS. As early as 1839, just a year after the 
first recorded pathological description of multiple sclerotic 
lesions, it was noticed that MS lesions appeared to involve 
altered vasculature or hemodynamics, an observation that 
was later made by Charcot himself.5 Intriguingly, an experi-
mental study in dogs published in 1935 claimed that when 
the cerebral veins were artificially obstructed, lesions 
developed that were “so striking [in similarity to MS lesions] 
that the conclusion appears almost inevitable that venular 
obstruction is the essential immediate antecedent to the 
formation of typical sclerotic plaques."6 The conclusion at 
the time was that such obstructions were likely a result of 
thrombosis, and as a result, treatment with anticoagulants 
was attempted, with mixed results.7  
In the years following the second World War, there 
was increasing recognition that the inflammatory compo-
nent of MS could be amenable to treatment. In 1969, 
researchers carried out a placebo-controlled study of 
adrenocorticotropic hormone (ACTH) in patients suffering 
from exacerbations of MS, and found that it was an effective 
symptomatic treatment.8 This paved the way for decades of 
further research into pharmacotherapeutical initiatives 
aimed at curbing the inflammatory process. The vascular 
component was all but forgotten, and today, the majority of 
drugs used to treat MS target the immune system, and 
although they are often touted as breakthroughs, retrospec-
tive studies have shown that they have only modest effects 
on established disease and somewhat questionable efficacy 
in preventing disease progression.9,10 
The modern attack on the dominant paradigm of MS 
began in late 2008, when Paolo Zamboni and colleagues 
showed that a particular set of extracranial venous anoma-
lies were found in MS patients, but not in controls.11 (It 
should be mentioned that Franz Schelling had attempted to 
resurrect the vascular theory of MS in 1986,12 but his efforts 
to secure funding for experimentation were frustrated, and 
it was left to Zamboni to take the lead more than twenty 
years later.) News spread quickly, and just a few months 
later, patients were discussing the new findings and seeking 
treatment for their venous stenoses and malformations at 
centres all over the world. Internet forums were abuzz with 
talk of a real breakthrough, as well as the personal anec-
dotes of those who had undergone treatment and found that 
it had helped their symptoms improve. In late 2009, 
Zamboni published the results of an open-label pilot study, 
which showed that venous angioplasty reduced symptoms 
and disability measures in those MS patients who had 
demonstrated cerebrospinal venous insufficiency.13 Notably, 
it should be pointed out that Zamboni does not argue that 
MS is not an auto-immune disease, but rather that the insult 
leading to inflammation and white matter lesions is often 
vascular in nature, and likely a congenital malformation.14 
Comparing the timeline of research into peptic 
ulcers with that of MS, it appears that the two share a 
similar trajectory. Both have their origins in a stage of pre-
paradigm science prior to the twentieth century, an ascen-
dant paradigm and a consequent programme of normal 
science within the last hundred years, and a period of 
potentially revolutionary science within the last few 
decades. In both cases, researchers operating outside the 
mainstream demonstrated findings compatible with older 
theories that challenged the dominant paradigm, and in 
both cases, their findings were met with skepticism. Lest we 
forget, even Marshall’s dramatic demonstration of the 
ulcerogenic properties of H. pylori (in 1984, he drank a 
culture of the bacterium and subsequently fell ill with an 
ulcer) was insufficient to convince the majority of clinicians; 
eight years later, an informal survey showed that two-thirds 
of gastroenterologists polled were still skeptical of the H. 
pylori claim.15 
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Conclusions 
 
As the debate over MS paradigms rages on, it is instructive 
to analyze the situation at play and understand what it may 
mean for medicine in general. Looking back on a century or 
more of modern medicine, it is likely that at least some 
answers to the pressing medical questions of our time have 
already been found, but have been neglected amidst the 
inevitable turmoil of shifting paradigms, ever-accumulating 
data, and the cognitive dissonance stemming from overzeal-
ous adherence to a particular set of ideas. Luckily, advances 
in technology and increasing access to more and more 
sources of historical research data have provided us with a 
rich reservoir of science to review and learn from. Whatever 
the final outcome of the MS debate, it is a foregone conclu-
sion that this will not be the last time forgotten research has 
its last laugh. 
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Addendum 
 
A precursor to this article was originally presented to the 
Harvey Club of London on April 20, 2010. 
 
The author invites readers to submit further examples of 
forgotten research at a new website created explicitly for 
this purpose: www.forgottenresearch.com. 
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Children and adolescents with spina bifida – a unique 
population 
 
Spina bifida (SB), meaning “split spine” in Latin, is the most 
common neural tube defect and the most severe congenital 
disorder compatible with life.1 During the third to fourth 
week of embryonic development, the central nervous 
system begins as a neural plate and fuses into a neural tube. 
SB is the failure of this neural tube to close and results in 
three different categories of defects: occulta, meningocele 
and myelomeningocele, the latter being the most severe and 
the focus of this article. Fifty years ago, the prognosis of an 
infant with myelomeningocele was grim as only ten percent 
were expected to survive their first year.2 Today, survival 
into adulthood exceeds 85% due to advances in the manage-
ment of complications.1 While this is certainly a success in 
neurosurgical medicine, deterioration in adulthood is 
common in these survivors. One of the greatest challenges 
remaining is the continuity of care between paediatric and 
adult services, which requires a functional multidisciplinary 
team.  
Morbidity in the aging SB population is a complex 
combination of physical, emotional and developmental 
obstacles. The long term physical effects of SB include 
muscle weakness or paralysis below the level of the lesion, 
loss of sensation, and loss of bowel and bladder control.3 
Following repair of the myelomeningocele, 70-80% of 
infants develop some degree of hydrocephalus, which is 
treated by implanting a shunt shortly after birth.4 If hydro-
cephalus is untreated, or if the shunt later malfunctions, 
excess fluid may result in permanent brain injury, seizures, 
or blindness. Unrecognized shunt malfunction is the leading 
cause of death in adults with SB.4,5 This is a topic that adult-
centered physicians must be educated in when caring for 
patients with SB.  
Concerning the emotional development of children 
with SB, independent mobility is an important factor in 
determining quality of life. The level of the lesion corre-
sponds to prospective independent mobility. For lesions 
above L2, loss of quadriceps and iliopsoas muscle function is 
typical and wheel chair dependence is expected. 6 However, 
lower lumbar and sacral lesions are usually compatible with 
ambulation,7 for which early physiotherapy and orthopedics 
consultations are crucial.8 Ambulation may mitigate the 
decline in activity through adulthood resulting from obesity, 
spinal and foot deformities including scoliosis and clubfoot, 
and respiratory compromise. In a 2004 cohort study of 117 
patients, 30% were ambulatory at 30 years follow-up, of 
which 88% had lesions at L5 or below.9 This highlights the 
importance of early intervention and appropriate rehabilita-
tion in response to changes that occur over time.  
Another important area of treatment for people 
living with SB is the lifelong management of urinary 
incontinence and impaired sexual function.10 Sexual 
function may be reduced due to impaired neurological 
innervation, or the psychological effects of negative self-
image and incontinence anxiety. However, there are two 
common misconceptions that are held more by medical 
students and doctors than by the young adults themselves: 
that people with SB cannot be sexually active, and that they 
cannot have babies.3 Both are untrue. Healthcare profes-
sionals should provide the proper education and counsel-
ling of safe sex and contraceptive services and should 
address the increased risk of latex allergies. Family planning 
services and pap smears should also be readily available to 
patients with SB,3 and must be sensitive and specific to the 
emotional and physical needs of this unique population. 
As recently as twenty-five years ago, young children 
with developmental problems, including SB, faced an 
isolated homebound existence or were placed in often 
inadequate custodial facilities. A literature review also 
reveals that children with SB commonly have language 
deficits that often go unrecognized despite average intelli-
gence.11-14 In response, early interventions focusing on 
psychosocial and educational models have been empha-
sized. Failure in independent self-care has been found to be 
a hindering factor for employment in young adults with 
SB.15 It is therefore of vital interest to understand the factors 
leading to this failure in self care, whether they be physical, 
emotional, or developmental in origin, and to facilitate 
functional transition to adult life.  
 
Issues surrounding transition  
 
Knowledge and communication by paediatricians 
 
A study by Binks et al. outlines several barriers that prevent 
successful health care transition from paediatric to adult 
medicine for young adults with SB.16 One key point is that it 
is often difficult to sever the relationship between the 
paediatrician and the patient.16 The paediatrician is seen 
often, and builds trust and relationships with the entire 
family; this is the nature of paediatric care. Thus, there is a 
lack of incentive for all involved to discuss the process of 
leaving the paediatric system to transition to adult care.16 
This lack of communication inevitably results in a delay of 
the transition process until paediatric services are no longer 
applicable or available – in Ontario, when the patient turns 
19. This is contradictory to the literature, which suggests 
that transition should begin as early as possible – by the 
ages of 14-16.16   
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We believe there are several components necessary 
to facilitate an effective earlier transition.  First, it is 
essential that the paediatrician must have a realistic 
expectation of the duration of their patient’s care, since 
their expertise does not always translate to effective 
management of adults. It is in the best interest of the patient 
for the paediatrician to relinquish the patient’s care.  
Second, it is essential that care is taken by the 
paediatrician, with help of a multidisciplinary team, to 
prepare the child as best as possible for the physical and 
emotional challenges of adulthood.17,18 As mentioned, they 
include (but are not limited to), sexual health, social 
behaviours, alcohol and drug use, body image, mobility, 
employment strategies, anxiety and depression. Here, it is 
crucial for the information to be tailored to the patient’s age 
and stage of mental and physical development, which 
highlights the importance of expertise from multiple 
disciplines.  
Third, it has been shown that young adults with SB 
rarely feel comfortable navigating the adult health care 
system.16,17 Therefore, they are less able to advocate for 
themselves and are hindered in seeking the best possible 
care. Often, the paediatrician will continue to care for the 
patient.17 This has resulted in poorer health statuses of 
young adults with SB as compared to age-matched Canadi-
ans, whereas children with SB have the same health status 
as their Canadian counterparts.18 This inequality is due in 
part to a lack of preparation of the patient by their paedia-
trician and health care team. Therefore, early in the transi-
tion process, the patient must be made aware of the 
differences between paediatric and adult medicine, as well 
as the structure and function of the adult medical system. 
 
Training and abilities of adult care providers 
 
The second barrier outlined by Binks addresses the per-
ceived lack of knowledge of adult care providers surround-
ing the needs of young adults with SB. They may have little 
to no exposure to childhood diseases or their sequelae in 
adulthood. Young et al. notes that paediatricians are often 
concerned that their adult counterparts do not fully under-
stand or appreciate the nature and extent of SB.19 Addition-
ally, Sawyer et al. found that paediatricians specializing in 
SB felt that adult care providers did not fully grasp the 
needs of this population.17 
An ideal approach to transitioning would allow for 
several meetings between the paediatrician and future adult 
care provider, patient and patient’s family before the 
transition begins.18 These meetings would ensure several 
things. First, the family physician would receive all relevant 
information about the patient from three different sources: 
the paediatrician, the family and the patient. They would be 
more aware of the patient’s ability to manage their condi-
tion, as well as the role the family plays in the patient’s care. 
In such a way, the family physician is educated and may 
prepare to face the specific challenges of dealing with a 
childhood disease progressing into adulthood.  
 
Transition organization – multidisciplinary approach 
 
The ongoing goal is to ensure that quality health services 
are available to the patient with SB, given their physical, 
mental and emotional needs. Therefore, an organized, 
cohesive and coordinated system must be in place during 
and after their transition to adult care. Overall health of 
youth with SB is reported to be much higher than their adult 
counterparts.20 This indicates that adults with SB are not 
receiving adequate care. Professionals seen by patients with 
SB include nurses, speech therapists, occupational thera-
pists, physical therapists, dentists and many others, but the 
variety of care received is much richer for children with SB 
than adults.20 
Furthermore, in a study by Sawyer et al., several 
specific issues with the transition process itself were 
highlighted: the time gap between receiving paediatric and 
adult care, the sentiment that the adult health care practitio-
ners’ skills were insufficient (especially at the beginning), 
and the lack of reassured permanence of their care.17 
Coordinated multidisciplinary centers could help to address 
these issues. 
Studies have outlined different transition programs 
which include transition clinics.20 A study by Westwood, et 
al. showed that over 90% of children and adults with cystic 
fibrosis, another disease in which it is common to transition 
from paediatric to adult care, felt that a transition clinic 
would be helpful.21 These clinics unite family doctors, 
paediatricians, families and patients, and can provide links 
to additional resources such as counsellors and psycholo-
gists. With the current technology in electronic media that is 
available, the feasibility of meetings between multiple 
individuals and disciplines becomes possible with confer-
ence calling and other internet-based solutions. The scope 
of practice may no longer be strictly limited by location, as 
these online networks become available to all professional 
communities.  
The ultimate benefit of such multidisciplinary clinics 
or teams would be to all patients with chronic paediatric 
conditions, who, thanks to advancing medical technology, 
are growing into their adult years. 
 
Conclusion 
 
Shunt problems and spinal cord-related symptoms typically 
account for a substantial amount of morbidity affecting 
young adults with SB and may be avoided if recognized 
early in their course. There are, however, also many 
important health education, vocational, and psychological 
issues that are specific to this age group. The transition from 
paediatric to adult care presents a huge challenge to the 
health care system itself. It must involve adequate resources 
and educated health care professionals to enable these 
paediatric patients to take the appropriate steps towards 
independence, maturity, and adult fulfillment.  
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Youth, adults and transitional patients with spina bifida 
References 
 
1. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. 
Spina bifida outcome: A 25-year prospective. Pediatr 
Neurosurg 2001;(34):114-120. 
2. Bamforth SJ, Baird PA. Spina bifida and hydrocepha-
lus: a population study over a 35-year period. Am J 
Hum Genet. 1989;44(2): 225–232.  
3. Sandler A. Living with Spina Bifida: A Guide for 
Families and Professionals. North Carolina: The 
University of North Carolina Press, 1997. 
4. Hunt GM, Oakeshott P, Kerry S. Link between the CSF 
shunt and achievement in adults with spina bifida. J 
Neurol Neurosurg Psychiatry 1999;67:591-595. 
5. Davis BE, Daley CM, Shurtleff DB. Long-term survival 
of individuals with myelomeningocele. Pediatr 
Neurosurg 2005; 41:186. 
6. Seitzberg A, Lind M, Biering-Sorensen F. Ambulation 
in adults with myelomeningocele. Is it possible to 
predict the level of ambulation in early life? Childs 
Nerv Syst 2008;24(2):231–237. 
7. Thompson DNP. Postnatal management and out-
come for neural tube defects including spina bifida 
and encephalocoeles. Prenat Diagn 2009;29:412–
419. 
8. Swank M, Dias L. Myelomeningocele: a review of the 
orthopaedic aspects of 206 patients treated from 
birth with no selection criteria. Dev Med Child 
Neurol 1992;34(12):1047–1052. 
9. Oakeshott P, Hunt GM. Lifestyle in adults aged 3 
years who were born with open spina bifida: 
prospective cohort study. Cerebrospinal Fluid Res. 
2004;1:4 
10. Koff SA, Gigax MR, Jayanthi VR. Nocturnal bladder 
emptying: a simple technique for reversing urinary 
tract deterioration in children with neurogenic 
bladder. J Urol. 2005;174(4):1629-31. 
11. Beeker TW, Scheers MM, Faber JA, Tulleken CA. 
Prediction of independence and intelligence at birth 
in meningomyelocele. Childs Nerv Syst 2006;22:33-
37. 
12. Wills KE, Holmbeck DN, Dillon K, McLone DG. 
Intelligence and achievement in children with 
myelomeningocele. J Pediatr Psychol 1990;15:161-
176. 
13. Fletcher JM, Barnes M, Dennis M. Language develop-
ment in children with spina bifida. Semin Pediatr 
Neurol 2002;9(3):201-208.  
14. Barnes MA, Dennis M. Discourse after early onset 
hydrocephalus: Core deficits in children of average 
intelligence. Brain Lang 1998;61:309-334. 
15. Van Mechelen MC, Verhoef M, van Asbeck FW, Post 
MW. Work participation among young adults with 
spina bifida in the Netherlands. Dev Med Child 
Neurol 2008;50:772–7. 
16. Binks JA, Barden WS, Burke TA, Young NL. What do 
we really know about the transition to adult-
centered health care? A focus on cerebral palsy and 
spina bifida. Arch Phys Med Rehabil 2007;88:1064-
73. 
17. Sawyer SM, Collins N, Bryan D, Brown D, Hope MA, 
Bowes G. Preliminary Report. Young people with 
spina bifida: Transfer from pediatric to adult health 
care. J Paediatr Child Health 1998;34:414-417. 
18. Sawyer SM, Macnee S. Transition to adult health care 
for adolescents with spina bifida: Research Issues. 
Dev Disabil Res Rev 2010;16:60-65. 
19. Young NL, McCormick A, Mills W, Barden W, Boydell 
K, Law M, Wedge J, Fehlings D, Mukherjee S, Rumney 
P, Williams JI. The transition study: A look at youth 
and adults with cerebral palsy, spina bifida and 
acquired brain injury. Phys Occup Ther Pediatr 
2006;26(4):25-45.  
20. Reiss JG, Gibson RW, Walker LR. Health care transi-
tion: Youth, family, and provider perspectives. 
Pediatrics 2005;115:112-120. 
21. Westwood ATR, Henley LD, Willcox P. Transition 
from paediatric to adult care for persons with cystic 
fibrosis: Patient and parent perspectives. J Paediatr 
Child Health 1999; 35:442-445. 
 
UWOMJ | 79:2 | Fall 2010 
 22 
 
Medicine and technology 
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Introduction 
 
Neuroprostheses are electronic human-computer interfaces 
that function to replace or enhance specific aspects of the 
central nervous system.  There are two main types of 
neuroprosthetics currently in use today: motor and sensory.  
Technological advances have made possible a wide variety 
of prosthetic devices that have greatly enhanced the quality 
of life of many patients who have lost sensory or motor 
functions. 
 
Sensory neuroprosthetics 
 
There has been a wide interest in neuroprosthetics that 
replace primary sensory organs. Perhaps the oldest and 
most successful example of a sensory neuroprosthetic is the 
cochlear implant. While not a perfect replacement, it has 
had a tremendous impact in restoring basic auditory 
function to patients. Research is also underway to develop a 
visual prosthetic device. However, limitations in current 
technology and our understanding of the visual pathway 
present  roadblocks in the development of an adequate 
device. 
Seminal work in developing an auditory prosthesis 
was conducted by French researchers in 1957, and involved 
stimulation of the auditory nerve with a single channel 
electrode.1 Even with this simple setup, the patient was able 
to distinguish monosyllabic words. More recent technolo-
gies informed by our understanding of the auditory system 
have dramatically improved this performance. For example, 
the portion of the auditory nerve that runs inside the organ 
of Corti is tonotopically organized; tones are spatially 
arranged by frequency. Cochlear implants take advantage of 
this by breaking incoming sound up into multiple frequency 
channels. Each channel is fed along its own electrode to the 
corresponding portion of the auditory nerve replicating the 
natural function of the cochlea. Just four frequency channels 
are sufficient to understand speech, which is remarkable 
considering that roughly 30,000 hair follicles normally 
stimulate the nerve.1  
Current implants have up to 22 channels, more than 
adequate for understanding speech, but still inadequate for 
auditory tasks such as music perception.2  A 2001 study in 
Nature demonstrated that improvements in music percep-
tion will require improvements in sound encoding.3 Not 
only does the auditory system decompose sound by 
frequency, it also separates sound into two components: a 
slowly varying frequency envelope suitable for speech 
recognition, and a rapidly varying fine structure used in 
pitch perception and sound localization. 
The development of a visual prosthetic has been 
much more difficult. Firstly, the amount of visual informa-
tion entering the eyes is more complicated and dense 
compared to the auditory system. While four frequency 
channels were adequate for functional hearing, having only 
four discriminate regions for vision is inconceivable. 
Researchers have suggested that a 10x10 array of pixels can 
restore just enough vision for navigation and object avoid-
ance,4 while as many as 1000 pixels are need to restore face 
recognition and reading.5 The retina is also an incredibly 
compact organ with a receptor cell density that cannot be 
easily replicated. One group demonstrated that a silicon 
microarray for nerve stimulation can be machined with 
electrodes that are 0.4mm apart, although this is still a far 
cry from the maximal cone density found in the fovea.6  
Despite the technological challenges of creating an 
artificial replacement retina, it still remains the primary site 
of visual prosthetic research for a number of reasons. 
Firstly, just as the cochlea is tonotopically organized, the 
retina has a natural spatial organization which simplifies 
prosthesis design. Secondly, a retinal approach takes 
advantage of natural visual processing that begins at that 
level, including colour perception and edge accentuation.7  
 
Motor neuroprosthetics 
 
Perhaps the most well known type of motor neuropros-
thetic is the artificial cardiac pacemaker.  Cardiac pacemak-
ers are devices implanted in the muscular wall of the heart 
as a replacement for the sinoatrial node, which is required 
to maintain the sinus rhythm of the heart.8  Another 
example of an autonomic neuroprosthetic device is the 
bladder control prosthesis used in patients with spinal cord 
injuries.  Although still in the experimental stage, neuro-
prosthetic devices implanted at various areas of the urinary 
tract attempt to replicate the original function of the urinary 
tract.  Controlled by an external transmitter, the device is 
implanted at the sacral anterior root ganglia of the spinal 
cord.  Signals sent from the device assist in bladder control, 
defecation and achieving and sustaining full erections in 
male patients.9 
In addition to autonomic devices, there are numer-
ous motor prosthetics under development.  The neuropros-
thetic device showing the most promise for motor control is 
an implantable computer chip called the Brain-Computer 
Interface (BCI).  The BCI can be implanted into the grey 
matter of the brain, the skull or outside the skull.  The BCI 
collects distinct EEG patterns generated by the patient when 
they imagine specific movements of paralyzed body parts 
and converts them into signals controlling prosthetic 
devices.10  The BCI essentially translates the intentions of 
the user into movement of the prosthetic device.11 Figure 1 
shows an example of a brain-computer interface currently 
in clinical trials. 
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Conclusions 
 
In addition to the sensory and motor neuroprosthetics that 
have been discussed above, there is a new area of research 
focusing on cognitive neuroprosthetics.  These devices aim 
to restore cognitive function to those who have suffered 
brain injury or paralysis due to trauma and those suffering 
from Alzheimer’s disease and Parkinson’s disease.  Dam-
aged brain tissue can be replaced by integrated circuits, 
which would help process information that would normally 
be done in the diseased region of the brain. 12   
Despite some difficult challenges in designing 
neuroprosthetic devices, such as the size of the device, 
power source and material interactions with human 
physiology, the work done thus far suggests a promising 
future . 
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Everyone gets angry from time to time, and for some people, 
anger seems to be the norm, rather than the exception. 
However, a relatively sudden shift in character to severe 
aggression is not considered ‘normal.’ This kind of aggres-
sive behaviour escalated to an extreme in the case of a 55-
year old Eastern European immigrant who, in a fit of rage, 
beat his wife to near-death with a hammer in 2008.1 Many 
similarly unfortunate events occur without attracting the 
attention of the medical community. This particular event, 
however, did not go unnoticed, as it involved a brain tumor. 
The patient has since been incarcerated for his actions, but 
could it be possible that the observed and documented 
changes in his behaviour were in fact the result of a tumor 
or its subsequent treatment? If medicine can provide an 
organic cause for his actions, should he be found criminally 
responsible for them? To be exact, should he even be 
prosecuted for an action he was not legally responsible for?  
In order to discuss the moral, medical and legal dilemmas 
that arise from such rare and complex cases, the pathogene-
sis of tumor-mediated aggression and its legal implications 
will be further explored.  
 
Case 
 
The patient presented with a one week history of head-
aches, aphasia and right hemi-paresis. A T1 weighted MRI 
and subsequent biopsy of the tumor confirmed a large 
glioblastoma (GB) in the left hemisphere, involving the 
frontal, temporal and occipital lobes.1 A glioblastoma is a 
grade 4 astrocytoma, characterized by high mitotic activity 
and necrosis or endothelial proliferation.2 The patient was 
subsequently treated for six weeks with concomitant 
radiation and chemotherapy. Throughout treatment, the 
patients’ family complained of new onset paranoia, despite 
no past psychiatric illness. His family denied any aggressive 
behavior. In spite of repeated suggestions from his physi-
cians to obtain a psychiatric evaluation, both the patient and 
his family refused. Although his motor functions improved 
throughout the treatment, to the utter vexation of his family, 
his emotional detachment failed to benefit from the shrink-
ing tumor.1 Upon further requests for psychiatric evalua-
tion, the patient discontinued (or withdrew) from treatment 
altogether. He was arrested eight months later for savagely 
beating his wife, in what can only be presumed to have been 
a fit of extreme, unbridled rage.1  
 
Physiology and behaviour 
 
The physiologic functions of the limbic system were 
discovered in the first half of the twentieth century.3 
Hughlings Jackson had delineated the temporal lobe 
(specifically, the amygdala) in the early 19th century as the 
origin for anger, aggression and rage.4 Studies demonstrat-
ing its role in human emotions were performed in 1963 and 
1977,  showing that stimulation of the amygdaloid nuclei 
induced a strong aggressive response.4  A mechanism of 
aggressive behavior production has been demonstrated in 
several recent studies on children with epilepsy, which can 
be extrapolated to those with tumor-associated seizures. 
These children with aggressive behavior and intractable 
partial epilepsy demonstrated glucose hypometabolism 
(which may be indicative of decreased neuronal activity) in 
temporal and prefrontal areas when compared to control 
subjects and nonaggressive children with partial epilepsy.5 
It is thought that in normal children, these areas suppress 
aggression triggered by the activation of limbic structures, 
and that loss of function in these areas results in loss of 
frontal lobe control.6  
It is well documented that tumors of the temporal 
lobe can cause seizures.4 Despite the rarity of their occur-
rence, some of these patients also manifest post-seizure 
aggression and other behavioral changes, which may be 
associated with the tumor. In documented pediatric cases, 
two children (both boys, aged 5 and 13) were found to have 
excessively aggressive behavior, which improved upon 
surgical resection of their tumors: a meningioma and a 
ganglioma, respectively, both in the right temporal lobe.6  
The patient in this case had cognitive impairments 
that are consistent with lesions in the left frontal, parietal 
and temporal lobes. Neuroimaging studies on aggressive 
and violent offenders have demonstrated a correlation 
between dysfunction of these areas and aggression and 
violent behavior. 7  
 
Social and legal implications 
 
Aggression and the gradation of related emotions have 
always existed within normal social behavior. It manifests in 
early infancy, as children procure from their caretakers the 
attention needed to survive.3 While in most cultures rage 
and aggressive outbursts are not tolerated, we must, as a 
society, consider the etiology of this aggression. The rapid 
transition a person can make from a state of reason to one 
of uncontrollable anger is rarely appreciated as a possible 
manifestation of disease.3 Underlying illness should be 
considered when the reaction is grossly disproportionate to 
the provoking stimulus or out of character for the patient. 
The possibility of a brain lesion leading to acts of extreme 
violence, while a rare occurrence, can have tremendous 
implications in the legal approach to such cases.  
The role of the physician must be established in 
treating patients who may potentially harm themselves or 
others as a result of their changed behavior. The ruling in  
Tarasoff v. Regents of the University of California (1976) 
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Brain tumour-related aggression 
determined that physicians have an obligation to protect 
public safety and can or must breach patient confidentiality 
to warn those potentially at risk of impending danger.8 As a 
result, patients who are demonstrating signs of aggressive 
or violent behavior require careful scrutiny throughout 
treatment and beyond, from both health care providers and 
family, in order to prevent a tragic outcome.  
In addition, the role of medical forensics in the 
judicial system is of increasing importance, as science and 
medicine are increasingly able to describe biological 
influences in the development of criminal behavior. Ad-
vancements in neuroimaging, such as CT and fMRI have 
afforded scientists the ability to search for organic causes of 
aggressive and violent behavior.7,9 In fact, the use of neuroi-
maging in criminal trials has increased as part of an attempt 
to mitigate penalties during sentencing hearings.11 However, 
not everyone is convinced of its use in a justice system 
based on free will. Some argue that searching for a root 
cause in every situation will decrease criminal liability. 
However, mitigating factors should not be ignored for the 
sake of upholding an unaccommodating penal system. Our 
judicial system relies on the principle of fundamental 
justice: when personal freedom will be restricted, the State 
has the onus to prove intent and act (Mens rea, actus rea). 10  
Thus, Greene and Cohen (2004) believe that: 
 
[N]euroscience will likely have a transformative 
effect on the law, despite the fact that existing legal 
doctrine can, in principle, accommodate whatever 
neuroscience will tell us. New neuroscience will 
change the law, not by undermining its current 
assumptions, but by transforming people’s moral 
intuitions about free will and responsibility.11 
 
The Canadian Criminal Code, Part XX.1, states that “A person 
can be found not criminally responsible by reason of mental 
disorder.”12 The legal test applied requires that the accused 
did not appreciate the nature and quality of the criminal act 
or omission or know that it was wrong.  Therefore, physi-
cians must be educated and have an enhanced awareness of 
the emotional and behavioral ramifications neurological 
disease and dysfunction may pose. In fulfilling their duty to 
advocate for patient welfare, physicians can promote new 
approaches, both medically and legally, to such situations, 
and potentially prevent wrongful convictions.  
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Profile of Dr. Michael Strong 
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Dr. Michael Strong is the current Director of the London 
Motor Neuron Diseases Clinic at the London Health Sciences 
Centre and the Arthur J. Hudson Chair in ALS Research. 
Commencing July 1st, 2010, Dr. Strong is stepping into the 
role of Dean of Medicine & Dentistry.  
Dr. Strong is truly one of Southwestern Ontario’s 
own, having been raised in Leamington, Ontario. His father, 
a microbiologist, worked as the director of the quality 
control program for Heinz Canada and then as a teacher at 
St. Clair College in Windsor. His mother worked as a nurse. 
Both had strong influences on Dr. Strong’s decision to 
attend Queen’s University, pursuing a degree in biochemis-
try, and his eventual enrolment in medical school soon 
thereafter. After receiving his M.D., Dr. Strong pursued 
training in neurology in London, Ontario, and post-graduate 
training at the National Institutes of Health, Maryland, 
which he described as “three of the best years of my life.” 
“When I initially began my residency training, it was 
not with a view towards becoming an academic.  I  
came to the University of Western Ontario after 
receiving my M.D. because I wanted to be a clinical 
neurologist and the program offered here was 
amongst the best in Canada.  I was, however, aware of 
the strength in clinical research in dementia at the 
time, so this had a role as well in the decision. 
Interestingly, the interview process for acceptance 
into the neurology training program reflected the 
focus of the program on training the next generation 
of clinical academics, so it was pretty close as to 
whether I would be accepted or not.  Not surprisingly 
however, given the strengths of the program, I fairly 
quickly found that I did have a considerable interest 
in the more academic aspects of Neurology.  This was 
in large part due to the mentorship of Dr. Arthur 
Hudson, my predecessor and head of the ALS clinic at 
the time.  
 Following completion of my residency training, 
I undertook a three year research fellowship at the 
NIH. I wanted to culture motor neurons to see if we 
could develop a model of ALS in vitro. Being at the 
NIH, we were afforded a great opportunity to 
undertake experiments that were high risk, but that, 
if successful, could potentially be very high yield. I 
was successful in both developing a model of cultur-
ing rabbit motor neurons — something not previ-
ously done — and in developing a new rabbit model 
of ALS.” 
 
Since then, Dr. Strong has won many prestigious awards and 
honours including recently being awarded the Sheila Essey 
award for ALS research in 2005 from the American Acad-
emy of Neurology and the Forbes Norris award in 2008 
from the International ALS/MND Alliance.  He is the only 
Canadian to have ever won both awards.  
With such a strong dedication to and interest in 
basic science research in his own career, we asked Dr. 
Strong if he would be making any changes to the Schulich 
medical curriculum with regards to the balance of clinical 
and research components: 
 
“Dean Herbert has left us with a very good educa-
tional program at Schulich; I hope to maintain and 
build upon that. I am also interested in promoting our 
research programs, and moving these to greater 
international recognition. When someone talks about 
the NIH, for example, there is immediate name 
recognition of various labs and research areas. While 
this does exist to some degree for Schulich,  I would 
like to expand this considerably. 
Our new president, Amit Chakma, is also very 
interested in making UWO known internationally. 
The best way to do that is to promote a few areas that 
can become renowned globally. Usually, that is 
achieved through a combination of strong educa-
tional and academic programs. The benefits of such a 
direction for Schulich are multiple.  We have to 
remember that we are living in a time of incredible 
scientific advancement, where technologies such as 
those embedded in genomics are dramatically 
changing not only how we practice medicine, but 
what our patients expect of us in terms of scientific 
knowledge.  So the advantage of educating students 
in a milieu of this caliber is that it will help to equip 
our students with the skills and the necessary 
comfort level to be able to process all the information 
that is available, or at least understand how to begin 
to interpret it.   
It isn’t my intent to push for every student to 
become academically focused, but I do want to allow 
for those that are to have the opportunities to 
develop their interest, much like the experience I was 
afforded.  Both educational and academic programs 
are integrated and necessary, and our goal is to 
develop physicians highly interested in both areas.”  
 
Current students are faced with difficult a dilemma – how 
much of our time do we invest in clinic and how much in 
research, if any. We asked Dr. Strong why he decided to 
pursue a clinical career, given his strong research back-
ground: 
 
“A large part of it was a personal motivation: my 
father had died from cancer and he was treated in 
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London, so that experience was ingrained in me. To 
be honest, I didn’t like the specialist that was treating 
[him], but then again, he couldn’t have done anything 
to make me happy considering the situation. My 
mother was also a nurse, and I saw her dedication to 
the healthcare profession as I grew up.  
Another positive influence was my biology 
teacher in grade 13, who had a Ph.D. from India. Since 
Ph.D.s from foreign countries were not recognized at 
the time, he taught biology at my school. He pro-
moted innovative teaching that was ahead of his time. 
One of my projects was to work on the brain with a 
pathologist at the hospital, looking at different areas 
of the brain using routine histological techniques and 
trying to see if there was some sort of anatomic 
correlate to the different lobes and functions. Pretty 
ambitious stuff for a high school student!   
It was also during this time that my father 
struggled with cancer, and on his hospital bed, he 
asked why I wasn’t thinking of going to Queens to 
study biochemistry. You have to understand that at 
that time, virtually all students in my high school 
ended up in either Windsor or London, with a very 
few making it as far away as Toronto.  Not at all like 
today. In hindsight, it was his way of telling me not to 
set boundaries for myself.  It was also around that 
time that I considered going into [the] priesthood, 
because I enjoyed working with people. A weekend at 
the seminary pretty much clarified where my career 
was going to head.” 
 
Your current responsibilities as a clinician-scientist and 
administrative leader sound very intimidating. What is a 
typical week in your shoes like?  
 
“Each week is highly variable. Key to this however is 
my family.   There are various activities that are 
seasonal and I try to organize my time around them. 
During the summer, I enjoy gardening with my wife, 
Wendy, and we play golf, often as a family. When my 
kids were younger I would take a week off to either 
go camping with them or spend time at a cottage. 
Eventually, as the kids became older, I could leave for 
a month at a time, and during that we camped all over 
Canada and the U.S. I was able to share time with my 
children that I will never get again. Better yet, the 
hospital didn’t fall down simply because I wasn’t 
there. It really was a great time in our lives.  
With regards to my average week, I can’t 
actually recall having one!  It is one of the great 
pleasures of being a clinician-scientist in that there 
are so many different challenges. I try as much as I 
can to get to my lab, so generally start each day at 7 
by killing off some paperwork, and then complete the 
day doing the same. In between is when I get to the 
lab or clinic.” 
With such a great balance between clinical work, research, 
and a great family life, we had to ask what motivated you to 
apply for the Deanship?  
 
“I loved my life, so it was not a quest for something 
better.  One of the reasons is that I do believe our 
next generation of physicians has to be very comfort-
able with balancing life, integrating science, and 
being a physician. We have an aging population that 
we have to deal with and we need people that are 
comfortable with balancing many things because it 
will not be easy in a time of tight fiscal resources. 
There is a significant research and academic compo-
nent to our field. It’s a difficult time in research, but 
we want to be able to take next generation of 
academics and tell them we can survive recessions 
and setbacks.  
I’ve done a lot of work to address our ability 
to do clinical research. We’re in a financial sector that 
is constantly squeezed. Our centre is supposed to do 
cutting edge research but we’re even struggling to 
deliver healthcare. I helped develop the Lifecycle 
Research Network (LRN), which is model for doing 
clinical research on a large scale across many 
different cities in the Southwestern Ontario area. The 
next thing to do as Dean is to bring about more push 
towards this.”  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a scientist, you are always on the cutting edge of new 
research. Where do you see your research career heading in 
the next 10-15 years, after your tenure as Dean? 
 
“It’s difficult to know if my research career will be 
like it is now. If you had asked 10 years ago, I cer-
tainly would not have predicted that my lab would be 
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leading in the areas in which it currently does.  The 
most difficult challenge for me while a Dean will be 
ensuring that I and my lab not only continue to lead, 
but that we keep abreast of all of the developments.  
If I get to the point in 10 years where I am no longer 
doing this, then I will need to seriously consider 
whether it might be time to take a step aside and 
hand it to the next generation. So, when all is done, I 
don’t know if I’ll be back in the lab, but I will be back 
doing clinical work.” 
 
Do you have any advice for current medical students on 
finding a balance between work and family? 
 
“What you’re establishing here is a life, and your 
habits will last a lifetime. Finding ways to enjoy your 
life is critical. There is a social side of being a medical 
student. There are lots of activities that are already in 
place for many of you, so my advice is to keep it up! 
You are all self-selected to be physicians. Finding a 
balance is a lifelong struggle. You’ll get older, wiser, 
have families, kids…and their life becomes a part of 
yours. It’s very difficult to balance all of that. We want 
you to know that we can provide role models, just as 
our previous generation has done.” 
 
For more information about the Lifecycle Research Net-
work, visit http://lawsonresearch.com/clinical_research/
lifecycle_research_network.html. 
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Status epilepticus: a neurological emergency 
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Epidemiology 
 
Based on United States data, it is estimated that 6,500 to 
15,000 people in Canada each year will have generalized 
convulsive status epilepticus (GCSE ),1,2 with a mortality of 
20%.3 The incidence of GCSE is highest in the first decade of 
life and after age 60.3 
 
Definition  
Epidemiological literature defines status epilepticus as a 
fixed and persistent seizure lasting at least 30 minutes, 4 the 
time interval after which irreversible damage occurs to 
neurons. However, clinically it is important to initiate 
treatment before 20 minutes and a more practical definition 
is: “either continuous seizures lasting at least five minutes 
or two or more discrete seizures between which there is 
incomplete recovery of consciousness.” 5 
 
Clinical features 
 
Initially, patients with status epilepticus will present with 
obvious seizure symptoms, such as tonic, clonic or tonic-
clonic movements. However, as the condition progresses the 
clinical manifestations become subtle and the only signs of 
an underlying disorder may be minor twitching or in some 
cases no motor activity.6 Electroencephalography (EEG) 
monitoring will be required to detect cerebral epileptic 
activity. EEG is also useful in distinguishing status epilepti-
cus from pseudoseizures, also known as nonepileptic status. 
Pseudoseizures clinically resemble a seizure, but do not 
show epileptic activity on EEG and may be precipitated by 
suggestions or commands. It is the other main condition in 
the differential diagnosis of multiple seizures and is 
implicated as the cause about half the time.7 
Physiologic changes that occur in GCSE can be 
temporally divided into two phases: Phase I (0-30 minutes) 
in which compensatory mechanisms are still intact, and 
phase II (>30 minutes) when more serious symptoms 
develop due to a failure of the compensatory mechanisms. 
This classification is clinically useful because the develop-
ment of phase II symptoms should prompt admission to an 
intensive care unit. (See Table 1). 
 
Pathophysiology 
 
The pathophysiology of status epilepticus remains largely 
unknown. An insight into the possible mechanism of  SE 
came from reports of patients who consumed mussels 
contaminated with domoic acid, an analogue of the excita-
tory neurotransmitter glutamate.8 This incident suggests 
that excessive activation of excitatory receptors can cause 
status epilepticus.  
Other evidence demonstrates that status epilepticus 
can be caused by substances, such as penicillin, which 
antagonize the neurotransmitter GABA.9 GABA is the main 
inhibitory neurotransmitter in the brain and so failure of 
effective inhibition may lead to prolonged seizures. Ulti-
mately, status epilepticus involves a disorder of the body’s 
normal mechanism to terminate a seizure, which can be due 
to excessive excitation or lack of inhibition.  
 
Causes - acute and chronic 
 
The causes of status epilepticus can be divided into acute 
and chronic. It is important to distinguish between them 
since the prognosis, management and response to treatment 
differs. 
Acute causes of status epilepticus include metabolic 
disturbances (e.g. electrolyte imbalances, renal faillure, 
sepsis), CNS infection, stroke, head trauma, drug toxicity 
and hypoxia. Chronic processes that cause status epilepticus 
include preexisting epilepsy, discontinuation of antiepileptic 
medication or sub-therapeutic levels of medication, and 
seizures due to chronic ethanol abuse. Other processes such 
as CNS strokes and tumours can present with status 
epilepticus after a latent period of weeks to years. 
Cases of status epilepticus due to chronic processes 
respond well to anticonvulsant medication. In contrast, 
seizures due to acute causes are typically difficult to control 
and have a higher mortality.10 
 
Management  
 
The management of status epilepticus includes standard 
measures that would be implemented in any medical 
emergency, including evaluation of the airway, breathing 
and circulation. The next steps in management are to order 
blood work and administer glucose, thiamine and antiepi-
leptic drugs.  
Relevant investigations to order include: CBC, 
electrolytes, calcium, magnesium, liver function, kidney 
function, serum levels of antiepileptic drugs, toxicology and 
clotting parameters. A lumbar puncture should be per-
formed if infection is suspected. 
Furthermore, two IV lines are recommended for 
administering glucose, thiamine, anticonvulsant drugs, 
normal saline and vasopressors. Thiamine is given to 
patients who are malnourished or have a history of alcohol 
abuse since they are at risk for Wernicke’s encephalopathy.  
Some special considerations in the management of 
GCSE are in order: 
 
• A priority in management is maintaining a patent 
airway and adequate ventilation.  
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• Patients should be protected from injury, however, 
restraints are not recommended as they may cause 
fractures.  
• Arterial-blood gas measurements are useful and 
often show a metabolic acidosis, which will correct 
itself once the seizures stop; sodium bicarbonate 
should be used only in extreme situations.11  
• Hyperthermia occurs frequently in about 29-79% of 
patients and should be treated immediately with 
passive cooling.  
 
 
 
Principles of drug therapy 
 
The initial treatment of GCSE is combined IV lorazepam and 
phenytoin; it controls 80% of seizures in patients with 
GCSE.12 
Benzodiazepines are fast-acting, potent antiepileptic 
drugs, and include  diazepam, lorazepam, midazolam, and 
clonazepam. Diazepam and lorazepam may both be consid-
ered in initial therapy, however lorazepam is preferred 
because of its duration of action of 12-24 hours versus 
diazepam’s 15-30 minutes duration of action.13 Adverse 
effects of IV benzodiazepines include respiratory depression 
and hypotension.  
Phenytoin is usually administered intravenously 
after a benzodiazepine (e.g. lorazepam). Adverse effects 
associated with phenytoin are cardiac rhythm disturbances 
(incidence of 7%) and hypotension (incidence of 29%). IV 
phenytoin may also rarely cause “purple glove syndrome” a 
tissue injury caused by venous irritation resulting in 
extravasation.  
Phenobarbital has a depressant effect on respiratory 
drive, level of consciousness and blood pressure. For these 
reasons, it is recommended only when benzodiazepine and 
phenytoin therapy fails, and administration should ideally 
be carried out in an intensive care unit. 
Status epilepticus that does not respond to a 
benzodiazepine, phenytoin or phenobarbital is considered 
refractory and will require therapy with propofol and/or 
midalozam.  
 
Out-of-hospital Treatment 
 
In situations when IV administration of drugs and monitor-
ing equipment are not available, treatment options include 
parenteral or rectal diazepam, sublingual lorazepam and 
intramuscular midazolam.  
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Phase I COMPENSATORY MECHANISMS REMAIN INTACT 
(0-30  
minutes) 
Extreme adrenaline or noradrenaline 
release 
  Cerebral blood flow and metabolism 
increase 
  Hypertension, hyperpyrexia 
  Hyperventilation, tachycardia 
  Lactic acidosis 
Phase II COMPENSATORY MECHANISMS START FAILING 
(> 30  
minutes) 
Cerebral autoregulation reduced 
  Respiration depressed 
  Cardiac arrhythmia 
  Hypotension 
  Cerebral edema 
  Hypoglycemia, hyponatremia 
  Kidney failure, rhabdomyolysis 
  Disseminated intravascular coagulation 
Table 1. Physiologic changes during GCSE.14 
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Introduction 
 
Stiff-person syndrome (SPS) is a rare neurological disorder 
involving episodic spasms often preceded by sudden 
stimuli, progressive stiffness of the limbs and trunk, and 
axial rigidity. Diagnosis of stiff person syndrome can be 
elusive due to the fact that patients tend to present with 
non-specific muscle complaints of stiffness, spasms and 
cramps.1 These symptoms have a large differential diagno-
sis, including infectious, toxic, neoplastic, vascular, genetic 
and autoimmune,2 and often other diagnoses are considered 
before stiff-person syndrome. Additionally, the stimuli-
induced spasms, social phobia and anxiety experienced by 
these patients can expand the differential to include 
psychogenic movement disorders.2-4 SPS causes significant 
disability and in many cases symptom relief can be achieved 
with treatment.1,2,5,6 As such, it is important to recognize 
possible cases of SPS and conduct the appropriate tests for 
diagnosis. Below is a case report exemplifying an approach 
to diagnosis of SPS. 
 
Case report 
 
A 66-year-old woman was admitted to the internal medicine 
service after an 18-month history of complaints of worsen-
ing stiffness affecting her lower extremities associated with 
pain. While the symptoms had started off mild, the patient 
rapidly progressed to requiring a walker for safe ambulation. 
The patient’s primary caregiver, her son, confirmed this 
history. Her son also stated that the patient was extremely 
fearful to attempt walking even when the symptoms were 
initially mild. The patient denied any symptoms affecting the 
trunk or her upper extremities. She denied any tremor, apart 
from that which occurred in the lower extremities upon 
standing. There were no complaints of autonomic dysfunc-
tion. Her speech was normal. By the time she arrived at the 
hospital, she was no longer able to ambulate even with a 
walker. 
Her past history was positive for a history of anxiety, 
chronic depression and auditory hallucinations, for which 
she was followed by the psychiatry service. Other health 
conditions included hypothyroidism, gastroesophageal reflux 
(GERD) and osteoporosis. The patient had been treated for 
her anxiety and depression with a combination of alprazolam 
0.5mg three times daily, citalopram 30 mg daily, and risperi-
done 0.5 mg daily for approximately one year. Other medica-
tions included rabeprazole, residronate, and levothyroxine. 
Because of the neuroleptic exposure (risperidone), 
the initial thought at admission was that the symptoms 
might be secondary to neuroleptic malignant syndrome. 
However, the psychiatry service saw the patient in consulta-
tion and felt that the lack of autonomic symptoms, focality of 
symptoms and lack of delirium argued against such a 
diagnosis. The patient did have an MRI of the head and spine 
performed which was unremarkable. Concerns were also 
raised as to whether or not the patient might be suffering 
from drug-induced parkinsonism because of the exposure to 
risperidone. The neurology service was subsequently 
consulted for a diagnostic opinion. 
When examined by the neurology service, the patient 
was oriented to time and place, and scored 30/30 on the 
MMSE. She was noted to have full extra-ocular eye move-
ments, but her pursuit movements were very saccadic in 
nature. The remainder of her cranial nerve examination was 
unremarkable. There was no evidence of tremor in the 
extremities at rest or with action. She was noted to be mildly 
bradykinetic in the upper extremities, but power was fully 
preserved. There was mild rigidity in the upper extremities 
on passive movement. In the lower extremities, the limbs 
were held in rigid extension, such that it was almost impossi-
ble to passively move the lower extremities. Her toes 
bilaterally were held in continual extension. Her sensory 
examination was unremarkable to pinprick, and only 
demonstrated elevated vibratory thresholds at the great toes 
bilaterally. Her reflexes were 2+ in the upper extremities, 3+ 
at the knees and absent at the ankles bilaterally. There was 
no evidence of ataxia. Her gait could not be assessed. 
After reviewing this woman, it was felt that stiff-
person Syndrome could be the underlying diagnosis. Anti-
GAD antibodies were obtained and were positive, supporting 
the clinical diagnosis of SPS. The patient was subsequently 
started on treatment with diazepam and baclofen achieving a 
dose of 15mg four times daily and 25mg three times daily, 
respectively. The patient noted a reduction in lower extrem-
ity tone and has been able to resume ambulation with a 
walker. The mobility in her legs has progressively improved 
while her pain has largely resolved with her current medical 
treatment. 
 
Discussion 
 
Clinical manifestations 
 
Stiff-person syndrome (SPS) is a rare neurological disorder, 
affecting the neuromuscular junction in a progressive 
manner, and has a spectrum of clinical presentations.6 
Several forms of SPS exist; the most common is classic SPS, 
involving auto-antibodies to glutamic acid decarboxylase 
(GAD).2,6 SPS, however, is a clinical diagnosis and thus the 
presence of GAD+ auto-antibodies is not a requisite for 
diagnosis.2,6 The classic form of SPS affects twice as many 
women as men and generally presents in the forth to sixth 
decades of life.7 The onset is typically insidious, but progres-
sive in nature. In the early stages of GAD+ SPS, patients 
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often present with lumbar lordosis and painful muscle 
spasms induced by stimuli,2 such as sudden noise, stress or 
touch.3,7,8 These spasms can cause falls and patients often 
experience fear of crossing the street and open spaces.2 It is 
currently unknown if the anxiety and phobias associated 
with SPS are caused by the pathogenesis or in response to 
the symptoms.2 SPS can become debilitating, with up to 65% 
of patients unable to perform routine daily activities due to 
symptoms of total-body stiffness, fear of falling and anxiety-
triggered spasms.5 Depending on the severity of symptoms 
or possibly failure of treatment, some patients require 
walkers or wheelchairs and may even become bedridden.2,5  
 
Pathophysiology  
 
In classic SPS, the majority of cases are associated with 
auto-antibodies against glutamic acid decarboxylase 
(GAD).1,2,6 The GAD enzyme is involved with the synthesis of 
the inhibitory neurotransmitter γ-aminobutyric acid 
(GABA) from the excitatory neurotransmitter precursor, 
glutamate.6 Antibodies against GAD prevent this conversion, 
thus dampening the GABAergic inhibitor pathway and 
causing accumulation of glutamate.6 It is proposed that the 
muscular symptoms of stiffness and spasms result from the 
auto-antibodies affecting interneurons in the spinal gray 
matter and intracortical inhibitory neurons.6,9  
 Glutamic acid decarboxylase is most abundantly 
present pre-synaptically in the CNS, but is also present in 
pancreatic ß cells.2,6 Interestingly, SPS is highly associated 
with autoimmune type I diabetes mellitus.2,6 In fact, the 
majority of patients diagnosed with SPS either have diabe-
tes or will subsequently develop it.2 While many diabetics 
have auto-antibodies against GAD, these auto-antibodies 
target a different epitope than in classic SPS and are present 
in low titres.2,6,8,9 Thus, the vast majority of diabetics do not 
develop SPS.2,9 When considering other autoimmune 
disorders in addition to type I diabetes, up to 80% of SPS 
patients will be affected by another autoimmune co-
morbidity.6 SPS responds well to immunotherapy, further 
supporting the autoimmune pathogenesis of SPS.2 
 
Treatment 
 
There are two general strategies to treatment of SPS; the 
first approach is to  treat the neurotransmitter imbalance 
directly and the second is to reduce the auto-antibody titres, 
treating the imbalance indirectly.9 In the first case, medica-
tions such as benzodiazepines and baclofen can be used to 
improve GABAergic inhibition.2,6,7,9 The doses of these 
medications however are limited by adverse cognitive side-
effects.9 Additionally, monoaminergic inhibitors, such as 
clonidine and tizanidine, can also improve symptoms.6 
 The second approach applies particularly to GAD+ 
SPS patients due to the  autoimmune nature of their 
condition. These patient may benefit from immunosuppres-
sive therapy such as steroids and intravenous immu-
noglobulin (IVIg).2,6 In a randomized, cross-over study, 16 
patients were treated with either placebo or IVIg for 3 
months, followed by a 1-month washout period and 
treatment with the alternative agent for 3 months.5 Signifi-
cant improvements in stiffness and heightened-sensitivity 
scores improved for both groups during the IVIg treatment 
period.5  Furthermore, a case has been reported describing 
significant symptom improvement using rituximab, an anti-
CD20 antibody that binds mature B cells and targets them 
for removal.10 Plasmapheresis is another option available 
for treatment of antibody-related SPS.2,6 This allows direct 
removal of excess auto-antibodies, however the beneficial 
effects are short-term.2,6  
 
Diagnosis  
 
SPS a very rare disorder, with an estimate of 1:1,250,000 
affected.6 Additionally, because its symptoms lead to a 
broad differential diagnosis, SPS can easily be mistaken for 
other disorders.2 In early stages, patients with SPS often 
present with reports of intermittent muscle spasm, but have 
a normal neurological exam.2 Additionally, if treated with 
diazepam, the EMG findings associated with SPS – continu-
ous low frequency motor activity –  are masked, which can 
further complicate the diagnosis.2,5,6,8 As the condition 
progresses, patients often development phobias and 
anxiety.2 This psychological aspect of SPS can lead physi-
cians to look for a psychogenic source for the problem.2-4 As 
such, SPS diagnosis can be elusive, but should not be 
forgotten in this clinical picture. While diagnosis of SPS can 
be made based on clinical findings, auto-antibody titres for 
GAD can support the diagnosis.2,6 Thus, although 60-80% of 
these patients will have serum anti-GAD antibodies, the 
absence of such antibodies does not rule out SPS.1 
 
Conclusion 
 
Stiff-person syndrome is an important diagnosis to consider 
when patients present with muscle stiffness, spasms and 
cramps.1 Patients with SPS often describe stimulus-
triggered spasms and falls, and phobia of open spaces, 
which may lead clinicians to misdiagnose the condition as 
psychogenic movement disorder.2-4 However, it is crucial to 
test for this condition as SPS causes significant morbidity 
and, in most cases, can be treated to alleviate symptoms.1,2,5,6 
Furthermore, SPS can present as a manifestation of an 
underlying neoplasm, such as breast cancer, SCLC, lung 
adenocarcinoma or mediastinal carcinoma, and may 
indicate the presence of or predisposition to diabetes.2 
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Introduction: optic nerve anatomy 
 
The optic nerve carries approximately 1.2 million afferent 
nerve fibres which originate in the retinal ganglion cells of 
the retina.1 Most of these synapse in the lateral geniculate 
body, while others are destined for the pre-tectal nuclei in 
the midbrain and other centres.  The optic nerve is approxi-
mately 50 mm long from globe to chiasm and can be divided 
into 4 subdivisions.2  First is the intraocular segment, which 
is called the optic disc or optic nerve head.  Behind the globe 
is the intraorbital segment, which is 25-30 mm long.  Here 
the nerve thickens with the addition of myelin sheaths that 
surround the nerve fibres, a function of oligodendroglia.  
Interestingly, the optic nerve within the orbit is S-shaped 
which allows the eye to move without stretching the nerve.  
The nerve will only become stretched if there is severe 
proptosis.   
After exiting the orbit, the optic nerve enters the 
optic canal to be directed upward and inward at a 45-degree 
angle towards its chiasmal destination.3 This is called the 
intracanalicular segment, and is approximately 6 mm in 
length.  Last is the intracranial segment, where the two optic 
nerves meet at the optic chiasm.  Here the optic nerve fibres 
from each eye decussate so that each optic tract carries 
fibres from the contralateral nasal hemiretina and ipsilat-
eral temporal hemiretina.3  
Based on the arterial supply of the optic nerve, it can 
alternatively be divided into two segments, anterior and 
posterior.  The anterior segment is simply the optic disc, 
which is supplied by the posterior ciliary arteries.4 There is 
also a minor arterial supply by an anastomotic circle called 
the circle of Zinn-Haller.5 The posterior segment consists of 
the intraorbital, intracanalicular, and intracranial subdivi-
sions and is supplied by a more complex system of periph-
eral (centripetal) and axial (centrifugal) vessels.5,6  Venous 
drainage of the optic nerve occurs almost exclusively via the 
central retinal vein. 
 
Examination 
 
Disorders of the optic nerve affect the main components of 
vision which are contrast, brightness and colour.3 There are 
four main tests used to evaluate these components and 
ultimately optic nerve function. 
 
Visual acuity 
 
This is performed with the aid of a Snellen chart, as the 
patient reads the smallest line of identifiable letters from a 
distance of 20 feet (6 metres). 
 
Colour plates 
 
In this test a series of colour plates are used to determine 
colour recognition in each eye.  Loss of signal transmission 
from cone receptors that are concentrated in the macula 
through the optic nerve is indicative of optic nerve dysfunc-
tion.  There can be a marked difference in colour recognition 
between eyes if there is unilateral optic nerve damage.  One 
should consider that approximately 5% of males have some 
degree of red-green colour blindness while performing this 
test.3 
 
Visual fields 
 
The simple screening examination is confrontation visual 
field testing.  The examiner stands approximately 1 metre 
from the patient with each person covering one eye and 
looking straight ahead.  A target finger is moved centrally 
until seen by the patient and this is repeated in several 
quadrants.  A counting fingers test may be more reliable and 
automated machine testing is the most sensitive means of 
detection.    
 
Swinging flashlight test  
 
This is one of the most valuable tests of optic nerve dysfunc-
tion available for the general physician.  The abnormality 
detected is a Relative Afferent Pupillary Defect (RAPD), also 
known as a Marcus Gunn pupil.  The key concept is that the 
optic nerve is responsible for the afferent limb of the 
pupillary reflex.  In a dim room, light shone on a normal eye 
will result in consensual and contralateral pupillary 
constriction.  The flashlight is then quickly moved to shine 
on the other eye and if there is optic nerve dysfunction in 
that eye then both pupils will abnormally dilate. 
 
Optic nerve disorders 
 
Ischemic Optic Neuropathy (ION)  
 
ION is the most common acute optic neuropathy in patients 
over 50.5,7 As the name implies it is caused by optic nerve 
ischemia, and patients classically present with abrupt onset 
of painless, unilateral visual loss.  It can be subdivided into 
anterior ION (AION) vs. posterior ION (PION) based on the 
location of the ischemia, or arteritic vs. non-arteritic based 
on the etiology of the ischemia.   
Arteritic AION is caused by systemic vasculitis that 
affects the optic disc, most commonly from temporal 
arteritis (TA).  Prompt diagnosis and treatment are impera-
tive as TA can be lead to blindness or death.  Headache, 
often severe, is the most common symptom associated with 
TA, occurring in approximately 50% of cases.8 Other 
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classical symptoms include jaw claudication, scalp tender-
ness, anorexia, weight loss, anemia, fever and visual loss.5 
Elevated inflammatory markers – C-reactive protein (CRP) 
and erythrocyte sedimentation rate (ESR) – strongly suggest 
the diagnosis, but temporal artery biopsy remains the gold 
standard and is recommended in all suspected cases.  The 
hemoglobin level should always be considered when 
reviewing the ESR as anemia may mask an elevated ESR.  
CRP, on the other hand, is not affected by hematologic 
factors or age.5 Treatment of TA is with high dose corticos-
teroids.  The vision loss is often more severe than its non-
arteritic counterpart, as 75% of patients with arteritic AION 
demonstrate visual acuity of 20/200 or worse.5  Transient 
visual loss, called amaurosis fugax precedes the profound 
visual loss in up to 30% of cases.5   
Non-arteritic AION is the most common form of ION.  
Caucasians account for 95% of cases,9 and individuals 
typically present in their 60’s.10  The exact pathogenesis is 
unknown. It is a presumed diagnosis that is made when TA 
is ruled out.  Visual loss may be less profound and partial 
field loss is common.  Contrary to what one might assume it 
is not triggered by an embolic event as in ischemic stoke.6 
There is no proven treatment for non-arteritic AION.  
Metabolic issues such as diabetic control and hypertension 
should be considered and treated appropriately. 
PION is defined as infarction of the retrobulbar 
portion of the optic nerve, and accounts for only 10% of 
cases of ION.7  It is characterized by a normal appearing 
optic disc that later becomes atrophic.11 TA is the most 
common cause of PION.  It is very important to rule out TA 
in all older patients who present with an afferent pupillary 
defect or unexplained visual field defect. 
 
Optic neuritis (ON) 
 
ON is characterized by inflammation of the optic nerve.  It 
must be thought of in cases of visual loss in younger 
patients. Clinical features of ON include visual loss, RAPD, 
optic disc edema and a classic central scotoma.12 Most 
patients improve without treatment, however intravenous 
steroids may hasten recovery and may reduce the risk of 
developing multiple sclerosis (MS).13 An MRI should be done 
to ascertain the long term risk of developing MS as multiple 
white matter lesions on an MRI increases the risk of 
developing MS to over 50%.14,15 
 
Glaucoma 
 
Glaucoma is a disease that causes nerve fibre layer loss 
within the intraocular portion of the optic nerve.  Cupping of 
the disc is apparent before the disc becomes pale. The exact 
mechanism of glaucoma is not fully understood, but it is 
highly associated with elevated intraocular pressure (IOP).  
There are two types of glaucoma, open-angle and closed-
angle.   
Open-angle glaucoma is a chronic condition account-
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  Optic Neuritis Arteritic ION Non-Arteritic ION Acute Glaucoma Open-angle  
Glaucoma 
Age <50 
  
>55 
  
50-70 
  
Mean 60 >65 increases with 
age 
Symptoms Pain, colour vision 
impaired greatly 
in affected eye 
Possible  
Symptoms of TA + 
decreased colour 
vision 
Decreased colour 
vision 
Nausea and  
vomiting, pain,  
coloured haloes 
around light 
Painless, visual 
field contraction 
noticed late 
Signs RAPD RAPD RAPD Fixed mid-
dilated pupil, red 
eye, hazy cornea, 
ciliary flush 
Cupping of disc 
Visual Loss Progressive, hours 
to days 
Sudden and  
profound 
Sudden, often on 
awakening 
Profound, within 
hours 
Gradual, over many 
years 
Visual Field Loss Diffuse  
depression,  
central scotoma 
Altitudinal Altitudinal   Scotomas, gradual 
peripheral loss 
Optic Disc  
Appearance 
1/3 patients have 
mild swelling 
(Normal if  
Retrobulbar) 
Swelling and 
chalky/white  
appearance 
(Normal if PION) 
Swelling with  
associated  
hemorrhages 
  Cup:Disc ratio >0.5, 
or >0.2 difference 
between eyes 
Table 1. Clinical summary of common optic nerve disorders. 
ing for the majority of cases.  Patients have chronically 
elevated IOP due to impaired drainage of aqueous humour 
from trabecular meshwork dysfunction.  Visual loss is 
gradual and is characterized by peripheral visual field 
contraction and scotomas (blind spots).  Generally the 
patient does not notice the visual field loss until late, which 
is why screening, especially in those with risk factors is 
important.  Risk factors include increasing age, family 
history, African-American race and IOP above 22 mm Hg.1   
Treatment is commonly with medications that either 
decrease aqueous production or increase drainage, and 
less commonly with surgery. 
Angle-closure glaucoma, also known as acute 
glaucoma, is a medical emergency.  It is most often caused 
by pupillary block between the iris and lens which then 
bows the iris forward blocking the angle and aqueous 
drainage through the trabecular meshwork.  Complete 
vision loss can occur within hours.  Patients typically 
present with a red and painful eye, nausea and vomiting, 
and they see coloured haloes around lights.1 Examination 
reveals a fixed, mid-dilated pupil, hazy cornea and firm 
globe.1  The iris is mid-dilated because this is where it can 
be in greatest contact with the lens to cause pupillary 
blockage and as the pressure rises, it becomes ischemic 
and remains mid-dilated.  Immediate medical treatment 
with topical pupillary constrictors, intravenous osmotic 
agents and oral carbonic anhydrase inhibitors is required, 
followed by a laser iridotomy to allow the aqueous to 
bypass the pupillary blockage.   
 
Summary 
 
Examination of the optic nerve and understanding its 
disorders are of great importance to the general physician, 
as misdiagnosis of optic nerve pathology can lead to 
permanent visual loss.  Table 1 summarizes important 
differences between the optic nerve disorders that one will 
encounter as a general physician. 
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Joseph Babinski is famous for his 1896 description of the 
Babinski sign, an abnormal plantar reflex associated with 
dysfunction of the pyramidal system. He is less well-known 
for his “other” Babinski sign: paradoxical raising of the 
eyebrow associated with closure of the eye, a feature typical 
of hemifacial spasm. 
As Babinksi noted in 1905, hemifacial spasm (HFS) is 
a disorder of painless, involuntary facial twitches confined 
to the muscles supplied by the facial nerve. While benign, it 
causes significant morbidity due to excessive closure of one 
eye, and the social effects of an abnormal appearance.1 
Unfortunately, facial twitches are often attributed to stress 
or anxiety, leading to a delay in diagnosis.2 A vigilant search 
for organic causes is essential when these symptoms arise, 
as highly efficacious treatment options for HFS are available 
and can significantly improve quality of life.   
HFS occurs more commonly in females (2:1) and has 
an overall prevalence of approximately 10/100,000. 1 The 
orbicularis oculi is the site of onset in the large majority of 
cases.3 Over months to years, the disease spreads to other 
muscles. 2 Spasms are described as clonic or tonic, are 
aggravated by stress, fatigue and anxiety, and persist during 
sleep.2 Disease is usually unilateral, and spasms are syn-
chronous in all affected ipsilateral muscles. 2 Bilateral 
disease occurs in a small minority of cases, and spasms are 
never synchronous bilaterally.2  
In most cases, hemifacial spasm is due to arterial 
compression of the root exit zone (REZ) of the facial nerve. 
This is similar to the proposed mechanism of trigeminal 
neuralgia, in which the trigeminal nerve is compressed in 
the REZ, causing demyelination and recurrent episodes of 
intense pain.6 In much the same way, compression of the 
facial nerve causes spontaneous irregular discharges, 
leading to involuntary muscle contractions. As well, non-
synaptic neural transmission (ephapsis) between branches 
of CN VII may occur, causing synkinesis.7  
Most commonly, the aberrant artery is the posterio-
inferior cerebellar artery (PICA), the antero-inferior 
cerebellar artery (AICA), or the vertebro-basilar artery (VB). 
In one series, these vessels were responsible 61%, 56% and 
27% of the time, respectively.8 The same study found that 
multiple vessels were responsible 40% of the time.8 
However, up to 25% of the population has vascular loops 
compressing CN VII, suggesting that this alone is insufficient 
to produce HFS.9 Vascular loop decompression surgery via 
the posterior cranial fossa is very effective in providing 
relief from spasms. For some patients, relief is almost 
immediate, while for others it can take up to a year follow-
ing surgery to see the full effects.  This delayed cure sug-
gests that HFS is not only due to mechanical compression. 
Demyelination of the nerve from the brainstem and hyper-
excitability of the facial nerve nucleus due to irritation from 
neurovascular compression may play a role.  The slow 
reversal of these plastic changes explains the delay.8 
Several other diagnoses can present in a similar 
fashion, including benign essential blepharospasm (BEB), 
focal motor seizures, and craniofacial tremor. These are 
differentiated largely based on clinical presentation, so a 
careful history and physical exam are essential. For exam-
ple, BEB often presents with spasms of the orbicularis oculi 
and adjacent muscles, which may be difficult to distinguish 
from HFS. However, BEB is often associated with eye 
irritation, vague ocular pain and photopobia.4 If the facial 
spasms are associated with body tremor, or a family history, 
craniofacial tremor is more likely.5 Focal motor seizures are 
implicated when post-ictal weakness and a greater involve-
ment of the lower face are present.5 If the clinical presenta-
tion is ambiguous, electrophysiologic studies and imaging 
can aid in the diagnosis.   
The characteristic sign of HFS on electrophysoiologic 
studies is a response in distant facial nerve branches 
following a stimulus to a single branch. This can be seen, for 
example, by spread of the blink reflex on stimulation of the 
supraorbital nerve to muscles other than orbicularis oculi. 
This is referred to as lateral spread response (LSR) and is 
attributed to spread of excitation at the site of ephapsis.11    
Rarely, HFS is caused by tumors, arteriovenous 
malformations, and venous compression.10 Because the risk 
of tumor is low, imaging may not be cost effective when the 
diagnosis is clear.2 However, a careful neurologic exam for 
focal signs is essential, and imaging is suggested if these are 
present or if conservative management fails. 2 Advanced 
MRI techniques, such as constructive interference in steady 
state, are effective at identifying neurovascular contact.2 
Imaging may also assist in surgical planning.2  
While spontaneous remission of symptoms is 
possible, it occurs in less than 10% of patients,2 and signifi-
cant effects on quality of life usually demand intervention. 
Several oral medications have been studied, including 
carbamazepine, anticholinergics, baclofen, clonazepam and 
haloperidol. However, sample sizes have been small and it is 
difficult to confidently interpret the results.2 The effects of 
oral medications are usually transient,2 and unacceptable 
side effects often occur.1 For many patients, this is not a 
viable treatment option. 
In contrast, many physicians consider botulism toxin 
(BTX) to be the treatment of choice.2 While few double-blind 
randomized studies evaluating BTX for HFS exist,1 the 
available evidence is encouraging. Park et al described an 
open-label study of 101 HFS patients, 98.6% of which had 
excellent results after injection of botulism-A.  The mean 
duration of effect was 16.5 weeks, with a range of 11-40 
weeks.12 In a review of the HFS-BTX literature, Jost et al 
found a total of 37 open case-control studies (N=2295) in 
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which good to excellent results were reported in 76-100% 
of patients.13 Adverse effects include facial droop, ptosis, 
diplopia, lid edema and ecchymosis,12 with facial weakness 
being the most common.1 
Microvascular decompression (MVD) of the facial 
nerve is the only truly curative option. It involves freeing 
the nerve from the compressing vessel(s) at the cerebello-
pontine angle. The offending vessel is gently mobilized away 
from the facial nerve and a small, rectangular piece of Teflon 
sponge is then interposed between the REZ on one side and 
the aberrant vessel(s) on the other.8   
While MVD has a high success rate (> 90% in some 
series), the recurrence rate remains up to 20%.2  Further-
more, the potential risks are significant, including facial 
nerve dysfunction, lower cranial nerve dysfunction, intrac-
ranial infections, cerebrospinal fluid leaks, and temporary 
or permanent damage to CN VIII.2 According to some 
reports, 7-26% of patients will suffer a degree of temporary 
or permanent hearing loss.2 A large study of 668 patients by 
Park et al found that 2.2% of patients experienced perma-
nent hearing loss, with 0.7% of these suffering total deaf-
ness.14  
According to several studies, monitoring of brain-
stem auditory evoked potentials (BAEP) reduces the risk of 
hearing loss complications.8 BAEP monitoring allows 
surgeons to watch for the increased latency of peak V and 
decreased amplitude of peak I, which are the early warning 
signs of excessive stretching of the cochlear nerve and 
impairment of the cochlear vascular supply, respectively.8 
This allows dangerous maneuvers to be stopped or cor-
rected, and appears to significantly reduce the risk of post-
operative hearing loss.8   
Intraoperative monitoring of lateral spread response 
(LSR) is more controversial.  The goal is to see disappear-
ance of the LSR when the aberrant vessel is moved away 
from the facial nerve.4 This can augment surgical decision-
making, and some authors suggest that it leads to improved 
outcomes.15 In 1987, Moller and Jannetta advocated routine 
intraoperative monitoring of LSR, contending that this 
would ensure adequate decompression. If LSR was observed 
at the end of the procedure, they reasoned, symptoms were 
likely to persist.8 Therefore, if the LSR does not disappear 
following decompression of the most obvious site, a search 
for a second site can be undertaken.7 In a study by Mooij et 
al, a second compression site was found in the majority of 
these cases.16 Several other authors advocate for LSR 
monitoring during MVD, including Sekula et al, who found 
that the probability of cure was 4.2 times greater if LSR was 
abolished during surgery than if it persisted.15  
Conversely, a number of studies have questioned the 
value of LSR monitoring. Joo et al examined 32 patients who 
had continuing LSR after MVD. Of these, 21 did not display 
HFS at 1-week follow-up. The authors argued that demyeli-
nation of the REZ may lead to a delay in normalization of 
electrophysiologic muscle responses, even when decom-
pression is effective.17 Similarly, Sindou examined outcomes 
in the longer term and found good results even in patients 
with persistent LSR at the end of MVD.8 One third of patients 
assessed became spasm free only after a significant interval 
(4 to 12 months). Since delayed effects of MVD are common, 
he argued, final assessment of outcome should not be made 
until 1 year post-operative.8 Neves et al noted that, in 
addition to delayed success, HFS can also recur after an 
MVD that was successful in terms of LSR disappearance. 
They found that intraoperative LSR changes did not corre-
late with HFS relief on the first post-operative day.7 How-
ever, they did find a correlation between absence of LSR at 
the end of surgery and the long-term efficacy of the MVD.7 
Whether elimination of LSR at the time of surgery predicts a 
good clinical outcome remains unclear.4 
Involuntary facial movements are often attributed to 
stress and disregarded.  An awareness of HFS and its 
presentation is essential, as HFS can result in severe social 
and functional disability4 and highly efficacious treatment 
options exist.  However, the benign nature of this disorder 
requires that these treatment options be carefully weighed.  
No treatment is without risk, but MVD in particular is an 
invasive solution that carries a risk of significant disability. 
A careful risk-benefit analysis must be undertaken in order 
to balance the potential of symptom relief with the risks of 
therapy. 
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Introduction 
 
Epilepsy is a chronic neurologic disorder characterized by 
recurrent, unpredictable seizures.1 It is estimated to affect 
0.5 – 1% of the world’s population.2 Epilepsy is not a 
singular condition, but instead a diverse family of disorders 
with many causes, all of which indicate underlying brain 
dysfunction.1 This heterogeneity has important implications 
with respect to treatment regimens and patient responsive-
ness. About 35% of patients with epilepsy are refractory to 
anti-epileptic drugs, and of that group, only a quarter may 
benefit from resective brain surgery.3 Deep brain stimula-
tion (DBS) may be a suitable treatment alternative for 
medically refractory patients who are not candidates for 
conventional surgical resection.  
 
Procedure 
 
DBS is a neurosurgical technique that uses electrical 
impulses to modulate or interrupt the inherent electrical 
activity of deep brain structures. Functional neurosurgeons 
use stereotactic MRI or CT scans to create a 3D coordinate 
system, allowing them to precisely locate anatomical targets 
and map out a suitable trajectory for reaching these targets.4 
An electrode (lead) is implanted in the intended deep brain 
structure, and a battery-powered implantable pulse 
generator (IPG) is embedded in a subcutaneous pocket 
positioned inferior to the clavicle. An insulated extension 
wire that runs up the neck connects the two devices. The 
IPG is programmed to relay electric current to the lead, 
which then stimulates the targeted deep brain areas.5 
Since acquiring FDA approval for the treatment of 
essential tremor and Parkinson’s disease in 1997,6 DBS has 
been used for dystonia,7 and has shown promise in the 
management of Tourette’s syndrome, obsessive-compulsive 
disorder, and treatment-resistant depression.8,9 The success 
of DBS in treating movement disorders has prompted 
interest in the potential for DBS as a treatment alternative 
for medically refractory epilepsy. 
 
Deep brain targets 
 
A brief summary of selected deep brain targets that have 
been under investigation in animal and human models is 
presented here.  
The substantia nigra pars reticulata (SNR) is known 
to be an important anticonvulsant site in rats. Pharma-
cologic animal studies have implicated the SNR as part of a 
‘nigral control’ system for epileptic seizures.10 Since then, 
DBS of the SNR has resulted in seizure suppression in 
animal models, though no human trials have been published 
to date.11 
The subthalamic nucleus (STN) directly innervates 
the SNR, thus providing a rationale for using stimulation to 
interfere with this neural circuit and disrupt epileptogene-
sis.12 Small human trials have demonstrated at least 50% 
overall seizure reduction using STN DBS.13-15 Further studies 
are needed to clearly establish its clinical efficacy and to 
determine whether the optimal stimulation target is the 
STN or the SNR itself.3 
Temporal lobe epilepsy is common in adults and 
frequently does not respond to medical therapy.2 While 
temporal lobectomy is an effective treatment for certain 
patients, surgical resection is less desirable for patients 
whose seizures involve bilateral foci and who may suffer 
memory issues as a result of the operation. An alternative 
treatment, hippocampal stimulation,  has been shown to be 
effective at reducing seizure frequency in patients with 
mesial temporal lobe epilepsy (MTLE).16,17 A double-blinded, 
randomized controlled study demonstrated a 15% median 
seizure reduction in four medically refractory MTLE 
patients for whom temporal lobe resection was contraindi-
cated. No adverse effects were reported, and one patient 
had a substantial long-term benefit.16 Another double-
blinded trial assessing hippocampal stimulation reported a 
50-95% seizure reduction in certain refractory MTLE 
patients. It is worthwhile to note that this stimulation did 
not result in memory deterioration.17 
Stimulation of two thalamic structures, the cen-
tromedian nucleus (CM) and the anterior nucleus of the 
thalamus (AN), has provided encouraging results in human 
trials. The CM is involved in modulating cerebral cortex 
excitability, and its location between cortical, limbic and 
basal ganglia structures makes it an attractive target for 
disrupting epileptic neural circuits. Recent human trials 
using CM DBS have reduced seizure frequency by 80-95 % 
in certain forms of epilepsy.18,19 
The AN’s anatomical connections suggest its poten-
tial as a vital target in the control of limbic epilepsy.11 
Several animal studies have confirmed the AN’s role in 
seizure propagation,20-22 and recent human trials have 
reported seizure frequency reduction using AN DBS.23-25 Of 
considerable interest is the recently published Stimulation 
of the Anterior Nucleus of the Thalamus in Epilepsy 
(SANTE) trial: a controlled, randomized, double-blinded 
trial that examined data from 110 patients in 17 U.S. centres 
who received bilateral stimulation of the anterior thalamic 
nuclei. During the first 3 months (double-blinded phase), 
half the patients received active stimulation and half did not. 
Those that received stimulation had a median decline in 
seizure frequency of 40.4%, compared to 14.5% for the 
control group. Then all patients received unblinded stimula-
tion for the remainder of the trial. After a two year follow-
up, 54% of patients had their seizures reduced by at least 
UWOMJ | 79:2 | Fall 2010 
               43  
Fe
a
tu
re
 a
rt
ic
le
 
Deep brain stimulation for epilepsy 
half, with 14 patients being seizure-free for at least 6 
months.26 
 
Complications 
 
DBS is an advanced neurosurgical procedure. The accuracy 
required and complexity involved makes it prone to 
complications. Adverse events can be categorized according 
to those arising from the operation, the implanted hard-
ware, or the electrical stimulation.27 
The most severe operation-related complication is 
intracranial hemorrhage. While the risk from implanting a 
single lead is low, sometimes multiple passages are required 
to ensure proper electrode placement, increasing the risk of 
symptomatic hemorrhage. With an average distance of 8cm 
from the cortical surface to most deep brain targets, utmost 
care must be taken to avoid major cortical blood vessels. 
Advances in imaging techniques, combined with thorough 
surgical planning, should help to ensure accurate lead 
placement with a minimal number of passages.27 
Anchoring the electrode to the skull too tightly may 
fracture the device, causing a short circuit and draining the 
IPG battery. On the other hand, constant head and neck 
motions create traction that may cause a loosely attached 
electrode to migrate from its desired target. Infections 
around the anchorage site, the IPG site or the extension 
region may also complicate the procedure and necessitate 
removal of the entire system. Antiseptic cleaning proce-
dures and prophylactic antibiotics may be used to curb this 
risk.27 
Stimulation-related complications include confusion, 
depression, and mood changes. These may arise from 
malposition of the electrode. Indeed, many of the deep brain 
targets are very small, and a misplaced lead, even by a few 
millimetres, may cause unwanted side effects. However, 
these events are mostly reversible and adjustable, and no 
major stimulation-related events have been reported thus 
far.28 
 
Open vs. closed loop stimulation 
 
The majority of the trials referenced in this paper 
have described DBS protocols of scheduled stimulation, 
where electrical current is delivered either continuously or 
cyclically (alternating on-off phases). This technique, 
referred to as ‘open-loop stimulation,’ delivers current 
without reference to ongoing electroencephalogram (EEG) 
activity.11,28 Recent data, however, suggest that chronic 
stimulation of certain brain regions may exacerbate seizure 
activity.29 Cyclic stimulation may ease this effect, but it also 
appears to be less effective than continuous DBS at reducing 
seizure frequency.30 
The protocol for using DBS to treat movement 
disorders is well-established.6 It relies on the concept of an 
epileptic brain fluctuating between a functionally normal 
state and an electrically abnormal one. Continuous stimula-
tion in this context thus acts to reduce the brain’s excitabil-
ity and maintain the functionally normal state. The stimula-
tion parameters for using DBS to treat epilepsy have largely 
followed those for movement disorders; however, the 
optimal protocol of DBS for epilepsy has yet to be deter-
mined.11 
An alternate strategy, called ‘closed-loop stimula-
tion,’ uses real-time seizure detection algorithms designed 
to interpret characteristic EEG cues representing the onset 
of epileptiform activity, and deliver electrical stimulation 
accordingly. There is growing evidence that this type of 
adaptive stimulation may be effective in humans.31,32 The 
development of reliable automated detectors will be 
required to ensure this method’s feasibility. 
 
Future directions 
 
The success of DBS in treating motor disorders, along with 
its expanding potential in the management of numerous 
other conditions, including epilepsy, has “brought functional 
neurosurgery back to an exciting era.”27 To firmly establish 
the role of DBS for epilepsy, optimal stimulation parameters 
and deep brain targets must be defined for the various 
seizure types and syndromes. A better understanding of the 
mechanisms by which seizures propagate and how electri-
cal stimulation has its effect will help to identify ideal 
surgical candidates and provide them with another thera-
peutic option worthy of consideration.  
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We sleep less than ever before.1 Occupational stress, familial 
commitments and an increasing number of distractions 
make it difficult for us to get the traditional eight hours of 
sleep. Many success stories about people sleeping only a few 
hours a day pressure us to think that we need to sleep less 
in order to be successful. Consequently, sleep deprivation 
has become such a common phenomenon that some people 
do not even realize their exhaustion. However, demanding 
schedules for doctors persist and trainees are forced to 
learn to sleep less. Apparently, the sleep quality and 
satisfaction among medical students and residents is 
relatively low, and many of them try to compensate for their 
lack of sleep by taking caffeine pills or coffee.2 Is sleep really 
something we should strive to cut back on? What are the 
consequences of frequent sleep deprivation on our ability to 
learn? In the following paper, we will look at the present 
knowledge of the role of sleep in memory consolidation.   
What is sleep? Although often perceived as a passive 
and inactive period, there are many physiological and 
neurological changes occurring during sleep. Sleep can be 
divided into rapid eye movement (REM) sleep and non 
rapid eye movement (NREM) sleep. The latter can be further 
divided into light sleep (stages 1 and 2) and slow wave sleep 
(SWS, stages 3 and 4). Sleep gets progressively deeper from 
stages 1 to 4. Each sleep cycle proceeds from lighter sleep to 
SWS and then to REM, and this SWS to REM cycle is re-
peated several times throughout the night. The first half of 
the sleep is predominantly SWS, whereas the last half of the 
sleep is predominantly REM.3  
 One of the most exciting and ongoing debates in the 
field of sleep research is whether or not sleep contributes to 
memory and if it does, how so? Memories are initially 
"encoded" when the brain engages in novel experience and 
action. These memories, however, require consolidation, 
which consists of stabilization and enhancement.3 A large 
number of studies offer a substantive body of evidence 
supporting the role of sleep in what is known as sleep-
dependent memory processing.  Evidence of sleep-
dependent memory has been found in many species, 
including humans and non-human primates, cats, rats, and 
mice using a variety of behavioural paradigms.4 These 
studies offer mixed conclusions about the role of sleep in 
simple, emotion-free declarative memories. For example, a 
recent study has shown that facial recognition memory was 
unaffected by subjects deprived of sleep for 35 hours.5 
However, other studies indicate that both SWS and REM 
sleep contribute to consolidation of complex, emotionally 
salient declarative memories. For instance, even though the 
aforementioned sleep-deprived subjects remembered 
familiar faces, they had much more difficulty remembering 
in which of the two sets of photos the faces had appeared.5 
In other words, their memory for the context of the faces 
was significantly decreased. It is interesting to note that 
while large doses of caffeine reduced the feelings of sleepi-
ness and improved the ability of the sleep-deprived subjects 
to remember in which set the faces had appeared, the level 
of recall was still significantly below the level of the non-
sleep-deprived subjects.5  
There is little doubt that sleep plays a critical role in 
post-training consolidation of procedural or skill mem-
ory.4  Recent studies have shown that memory stabilization 
largely occurs during wakefulness, whereas memory 
enhancement occurs primarily, if not exclusively, during 
sleep; through this enhancement either previously lost 
memories are restored or additional learning is produced, 
both without the need for any further practice.4 Thus, 
through sleep, the enhancement phase of memory consoli-
dation causes the active retention of memory instead of its 
decay.  
 
The enhancement phase occurs during slow wave sleep 
 
SWS is most prominent during early sleep. It is character-
ized by the appearance of slow oscillations, spindles and 
sharp wave-ripple field potential oscillations on an electro-
encephalogram (EEG).3 These various types of wave 
activities originate in different centres of the brain and are 
thought to play a role in memory consolidation. In the 
hippocampal-neocortical model of memory consolidation, it 
is proposed that the active memory accumulated during 
wakefulness is stored as fragments predominantly in the 
hippocampus as well as in neocortical regions.6 Studies have 
shown that by utilizing transcranial direct current stimula-
tion, one can artificially induce increased SWS and enhanced 
hippocampal-dependent declarative memory consolida-
tion.7 It is hypothesized that during periods of SWS, slow 
oscillations originating from the neocortex repeatedly 
stimulate the newly stored information in the hippocampus 
and cause their reactivation.6 This reactivation is associated 
with the presence of sharp wave-ripple activity as well as 
spindle activity.8 The sharp wave-ripple activity originates 
from the hippocampus, while the spindle activity originates 
from the reticular nucleus of the thalamus, which travels to 
the entire neocortex via the thalamocortical circuitry.8 The 
process of reactivation essentially allows recently stored 
memories in the hippocampus to help educate more 
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permanent stores within the neocortex. This is mediated by 
spindle activity, which causes changes in calcium permeabil-
ity of pyramidal neurons (important neocortical neurons in 
the relay of input into the neocortex).3 Varying calcium 
levels have been shown to play a role in the expression of 
genes that affect long-term plastic changes associated with 
memory formation and maintenance.9  
In addition to memory consolidation, SWS has also 
been shown to aid in the encoding and formation of new 
memory in the subsequent wakefulness period.10 It has been 
well characterized that neuronal synapses possess great 
plasticity and can alternate between long-term potentiation 
(LTP) and depression.3 Calcium influx and delivery of 
specific receptors to the excitatory synapses facilitate these 
changes.11,12 The delivery of excitatory receptors to the 
synapses increases the synaptic strength and LTP, and this 
process is found to be more prominent during wakefulness 
in rats.11 This indicates that strong synaptic circuits cannot 
be maintained indefinitely due to limitations on energy, 
space, and saturation.11 Hence, the down-regulation of these 
receptors observed in SWS may be crucial for the homeosta-
sis of neuronal plasticity. However, this does not mean that 
sleep is devoid of LTP activities, and it is hypothesized that 
this process occurs during REM sleep. Animal studies have 
shown that exposure to a novel environment during 
wakefulness is associated with increased expression of 
immediate early genes during sleep.13 They in turn activate 
several receptors, which induce LTP. The process of 
"transferring" memory from its temporary hippocampal 
storage sites to its more permanent neocortical sites has 
also been suggested to play a role in priming hippocampal 
structures for the formation of new memories.14 fMRI 
imaging studies support this hypothesis by showing 
significant reduction in hippocampal activity following sleep 
deprivation during memory encoding activity compared to 
controls.14 Furthermore, recent studies evaluating the effect 
of SWS on the acquisition of temporal memory (memory of 
when events occur) showed a significant deficiency in 
temporal memory recall in the sleep deprived group 
compared to controls.15 This experiment controlled for 
confounding variables such as stress from the lack of sleep 
by allowing a 36 hour sleep ‘rejuvenation’ period for both 
groups. Furthermore, it has been shown that even a nap of 
significant duration, containing SWS, shows significant 
correlation with enhanced declarative memory.16 Moreover, 
physiological and behavior studies have shown the impor-
tance of SWS on the consolidation of new and old memories 
and thus can be thought to play an integral role in the 
effective acquisition and storage of new information.    
 
The role of rapid eye movement sleep  
 
REM sleep represents the late stage of the sleep cycle. It is 
characterized by reduced muscle tone and fast, low-voltage 
EEG waves.17 Early behavioural studies led to the develop-
ment of the hypothesis that REM sleep is involved in 
memory consolidation.18 Following a period of intense 
learning, it has been shown that there is an increase in REM 
density and the number of rapid eye movements.19 Further-
more, altering the levels of REM during sleep may affect 
memory acquisition. Donepezil, an acetylcholinesterase 
inhibitor used for treatment in Alzheimer's, induces an 
increase in REM sleep. This increase is linked to an enhance-
ment of memory performance.20 In contrast, a decrease in 
REM sleep inhibits learning, as seen in REM deprivation 
studies in both animals and humans. Physiologically, the 
discharge patterns in the hippocampus during training on a 
circular track task (a common experimental setup to test for 
spatial recognition memory) are also mimicked during REM 
sleep, which suggests that the learned task is replayed while 
asleep.21 The increase in the amount of REM sleep post-
learning, change in memory performance by altering the 
amount of REM sleep. and evidence of learning during REM 
sleep provide support for the aforementioned hypothesis. 
Recently the role of REM in memory consolidation 
has been called into question. The REM depression studies 
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have been criticized for the use of the "platform-technique," 
where an animal is placed on a small platform surrounded 
by water. As the animal enters the REM stage of the sleep 
cycle, its muscles relax causing it to fall in and thereby 
disrupting that stage of sleep. This technique produces a 
high level of stress in the animal, resulting in confounding 
factors such as hyperactivity, anxiety and irritability. 
Furthermore, depressed patients treated with monoamine 
oxidase inhibitors, which block REM sleep, do not show 
memory impairments.22 The inconsistent results with 
respect to the REM sleep-memory consolidation hypothesis 
have led to a debate in the field, with some suggesting that 
REM sleep is only important for procedural memory.  
  
Conclusion 
 
Despite the controversial role of REM sleep in memory 
consolidation, there is no doubt that sleep has a profound 
influence on how we learn. Medical students are constantly 
torn between the need to stay up and learn those extra few 
pages, and getting the sleep required. However, many 
studies have shown a decrease in memory acquisition and 
consolidation with a lack of sleep. Although staying up late 
may help students get the few extra points needed to pass a 
course, it will hinder the ability to retain what has been 
learned. Future doctors must optimize learning habits today 
to take better care of patients tomorrow.  
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